Podcasts about classically

(00:00-31:17) We like good tidings. Tim's voice hits better than Folgers. Blues first round schedule is out. Sebastian Maniscalco & Katt Williams. Do the multiple days off benefit the Blues? Game 6 on a Friday night would be a pony. Doug and Martin in their pastels. Lower Arnold is a wiffleball hotbed. Dickie V at the MAC. (31:26-51:54) Canada is not a serious place. Favorite Canadians. Redbirds fall to the Mets. Audi of Oli Marmol spinning a positive from the loss. Classically trained in journalism. Audio from Jomboy talking about the Cardinals. Jackson can't attend The Plow Wedding. Maty Mauk new football coach at Principia High School. (52:03-1:05:21) People are sending in pictures of their wives for The Real Housewives of TMA. What's the age range on this thing? We failed to help The Baseball Bachelor. Lix says BBB can't get in. This is Daddy's time of year. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episode 188: RSV Management and PreventionDr. Sandhu and future Dr. Mohamed summarize the management of RSV and describe how to prevent it with chemoprophylaxis and vaccines. Dr Arreaza adds some comments about RSV vaccines.Written by Abdolhakim Mohamed, MSIV, Ross University School of Medicine. Comments by Ranbir Sandhu, MD, and Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.What is RSV? -The Respiratory syncytial Virus (RSV) is an enveloped, negative-sense, single-stranded RNA virus of the Orthopneumovirus genus within the Pneumoviridae family. -RSV is a major cause of acute respiratory tract infections, particularly bronchiolitis and pneumonia, in infants and young children, and it also significantly affects older adults and immunocompromised individuals. -RSV infections cause an estimated 58,000–80,000 hospitalizations among children younger than 5 years and 60,000–160,000 hospitalizations among adults older than 65 years each year.-RSV is highly contagious and spreads through respiratory droplets and direct contact with contaminated surfaces. The virus typically causes seasonal epidemics, peaking in the winter months in temperate climates and during the rainy season in tropical regions. -Virtually all children are infected with RSV by the age of two, and reinfections can occur throughout life, often with milder symptoms.-Per the 2014 Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis, from the American Academy of Pediatrics, the most common etiology of bronchiolitis is RSV. -About 97% of children are infected with RSV in the first 2 years of life, about 40% will experience lower respiratory tract infection during the initial infection. Other viruses that cause bronchiolitis include human rhinovirus, human metapneumovirus, influenza, adenovirus, coronavirus, and parainfluenza viruses.When is RSV season?-Classically, the highest incidence of infection occurs between December and March in North America. Per CDC, there were typical prepandemic RSV season patterns, but the COVID-19 pandemic disrupted RSV seasonality during 2020–2022. -Before we dive into the seasonality patterns, for context, in order to describe RSV seasonality in the US, data was gathered and analyzed from polymerase chain reaction (PCR) test results reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS) during July 2017–February 2023. -Seasonal RSV epidemics were defined as the weeks during which the percentage of PCR test results that were positive for RSV was ≥3%. Per 2017–2020 data, RSV epidemics in the United States typically follow seasonal patterns, that began in October, peaked in December or January, and ended in April. -However, during 2020–21, the typical winter RSV epidemic did not occur. The 2021–22 season began in May, peaked in July, and ended in January. -The 2022–23 season started (June) and peaked (November) later than the 2021–22 season, but earlier than prepandemic seasons. CDC notes that the timing of the 2022–23 season suggests that seasonal patterns are returning toward those observed in prepandemic years, however, warn that clinicians should be aware that off-season RSV circulation might continue.Treatment of RSVSome key points of the 2014 pediatric guidelines from the American Academy of Pediatrics.-AAP strongly do not recommend beta agonists or steroids for viral associated bronchiolitis because of no significant improved outcomes. “Clinicians should not administer albuterol (or salbutamol) to infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Strong Recommendation).”-Epinephrine is not recommended for infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Strong Recommendation).-Nebulized hypertonic saline should not be administered to infants with a diagnosis of bronchiolitis in the emergency department (Evidence Quality: B; Recommendation Strength: Moderate Recommendation), but hypertonic saline may be administered when they are hospitalized (Evidence Quality: B; Recommendation Strength: Weak Recommendation [based on randomized controlled trials with inconsistent findings]).-Chest physiotherapy should not be used in infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Moderate Recommendation).-Antibiotics should not be administered in bronchiolitis unless there is a concomitant bacterial infection, or a strong suspicion of one (Evidence Quality: B; Recommendation Strength: Strong Recommendation).-Oxygen therapy may not be administered if the oxyhemoglobin saturation exceeds 90% in infants and children with a diagnosis of bronchiolitis (Evidence Quality: D; Recommendation Strength: Weak Recommendation [based on low level evidence and reasoning from first principles]).-Clinicians should administer nasogastric or intravenous fluids for infants with a diagnosis of bronchiolitis who cannot maintain hydration orally (Evidence Quality: X; Recommendation Strength: Strong Recommendation).How do we prevent RSV?Infant Immuno-prophylaxis:A clinical trial in 2022 demonstrated that a single injection of nirsevimab (Beyfortus®), administered before the RSV season, protected healthy late-preterm and term infants from RSV-associated lower respiratory tract that required medical treatment. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life.Additionally, on August 3, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended nirsevimab for all infants younger than 8 months who are born during or entering their first RSV season and for infants and children between 8-19 months who are at increased risk for severe RSV disease and are entering their second RSV season. On the basis of pre-COVID-19 pandemic patterns, nirsevimab could be administered in most of the continental United States from October through the end of March.Maternal Vaccination: The CDC recommends the administration of the RSVPreF vaccine to pregnant women between 32 0/7 and 36 6/7 weeks of gestation. This vaccination aims to reduce the risk of RSV-associated lower respiratory tract infection in infants during the first 6 months of life.At this time, if a pregnant woman has already received a maternal RSV vaccine during any previous pregnancy, CDC does not recommend another dose of RSV vaccine during subsequent pregnancies.Older individuals: -Each year in the U.S., it is estimated that between 60,000 and 160,000 older adults are hospitalized and between 6,000 and 10,000 die due to RSV infection-ABRYSVO's approval will help offer older adults protection in the RSV season.-On June 26, 2024, ACIP voted to give these recommendations: all adults older than 75 years and adults between 60–74 years who are at increased risk for severe RSV disease should receive a single dose of RSV vaccine (Abrysvo®).Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Hamid S, Winn A, Parikh R, et al. Seasonality of Respiratory Syncytial Virus — United States, 2017–2023. MMWR Morb Mortal Wkly Rep 2023;72:355–361. DOI: http://dx.doi.org/10.15585/mmwr.mm7214a1Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. PMID: 35235726.Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, Johnson DW, Light MJ, Maraqa NF, Mendonca EA, Phelan KJ, Zorc JJ, Stanko-Lopp D, Brown MA, Nathanson I, Rosenblum E, Sayles S 3rd, Hernandez-Cancio S; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502. doi: 10.1542/peds.2014-2742. Erratum in: Pediatrics. 2015 Oct;136(4):782. doi: 10.1542/peds.2015-2862. PMID: 25349312.CDC, per their published article Seasonality of Respiratory Syncytial Virus — United States for 2017–2023, in the United StatesWhat U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.Debessai H, Jones JM, Meaney-Delman D, Rasmussen SA. Obstetrics and Gynecology. 2024;143(3):e54-e62. doi:10.1097/AOG.0000000000005492.Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged

The last day of Spring Break deserves a real party, doesn’t it? Well, Chinese American Bear has the honey pot for just that. Classically trained Anne Tong immigrated from China with her family when she was around six years old, and after moving around several states in vastly different parts of the country, the family […] The post Chinese American Bear: “Feelin’ Fuzzy” (Live At Scholz Garten) appeared first on KUT & KUTX Studios -- Podcasts.

ABOUT RACHEL:Rachel McVay is an American actor rooted in UK training. Classically trained, with an MFA from the prestigious Bristol Old Vic Theatre School and a BFA in Theatre & Dance, Rachel also studied with the Royal Shakespeare Company and RADA. She has made her mark as a dynamic stage, TV, & film actor, often employing her skills in stunts, stage combat, and dance.With an affinity for Shakespeare, Tarantino, and Ryan Murphy, Rachel's proudest roles include the "fierce" Queen Elizabeth in Richard III, the "magnificent" & "regal" Beatrice in Much Ado About Nothing ("McVay stands out as Beatrice"), and the lead in the award-winning film, Broken Nails, in which she plays a boxer/dancer who struggles with self love in overcoming cancer.Some of her TV credits include Westworld, Forever, and The United States of Tara. Teaching/directing credits include Northern Stage, Stagedoor Manor, Bristol Old Vic Theatre School's Young Artists Academy, A Noise Within, Blue Lake Fine Arts Camp, amongst others across the country.Connect with Rachel on social:https://www.instagram.com/therachelmcvay/www.imdb.me/rachelmcvayConnect with me and learn about my services at Hollywood Bound Actors:⁠https://hollywoodboundactors.com/⁠Learn about my signature course Book More TV ® https://bookmoretv.com/

Emily Williams, dean of faculty at Kootenai Classical Academy in Post Falls, Idaho, delivers a lecture on the history of science education and how teaching classically can help students strive for what is true, good, and beautiful. This lecture was given at the Hoogland Center for Teacher Excellence seminar, “The Art of Teaching: The Sciences” in November 2024. The Hoogland Center for Teacher Excellence, an outreach of the Hillsdale College K-12 Education Office, offers educators the opportunity to deepen their content knowledge and refine their skills in the classroom.See omnystudio.com/listener for privacy information.

IAN UNPLUGGED 2506 020825 Line UpOn Classically Yours, Jyoti celebrates romance and Valentine's Day with songs based on Pahadi Raag.

IAN UNPLUGGED 2502 011125 On Sat, January 11, 2025 from, 3 - 4 pm on “IAN UNPLUGGED” on Indo American News Radio (www.IndoAmericanews.com), on Classicallly Yours, Jyoti pays musical homage to creative icons Houstonian Bapsi Sidhwa, Shyam Benegal and Mohammed Rafi. The prgram starts a little late due to a traffic delay on the 59 freeway.

 In this week's episode we take a closer look at the fundamental problem most academics have when it comes to understanding Midrashim. We also start looking at the Five Basic Elements of learning Tanach. The first element is understanding the words and their meaning. Classically we start this with Rashi and the Ramban. Why do we do this?  Nach Yomi: Join R' Wittenstein's Nach Yomi on WhatsApp. We learn a perek a day five days a week, with a nine minute shiur covering the key issues. Click here to join!  For tours, speaking engagements, or sponsorships contact us at jewishhistoryuncensored@gmail.com PRODUCED BY: CEDAR MEDIA STUDIOS  

Send us a textHumans are tribal, we are a species that thrives in the collective, where individual skills are amplified by the resources and assistance of others. Throughout our known history, we've been organized into different groups for specific purposes, whether that be family, relational, cultural or fulfilling our basic needs. Classically presented as the Dunbar number, named after a notable British anthropology professor, humans have Neo-cortexes that support a loose acquaintance level of 150 persons and smaller intimate groups of 12-15. These statistics are reflected in military & business organizational systems, the rifle company normally will not exceed 150 personnel and start-ups are often seen as losing culture, vibe and purpose when they exceed Dunbar's number. This research is recent, first published in 1992 and continues to inform our understanding of the need for community, to belong, a sense of place. I've written at length about the value of social capital, our propensity and opportunity to create bonds, and its importance to the safety and future of communities under duress. The body of research in disaster and emergency management (DEM) is reasonably homogenous in that it posits human connections, the value placed on our sense of belonging is one of, if not the key variable, in determining the quality of our post event outcomes. Whether we pontificate on how neanderthals managed earthquakes, or we examine the last 300 years of data on human tribal response to significant exogenous shock, I will argue that the value of community is unquestioned, but under-utilized.We transformed from a duty to contribute to and build our tribe to entitlement to draw from it. A slow, deliberate, methodical change in our culture that now has a nation of what is colloquial referred to as a collection of individual dependasaurus. This extends to how we have changed our political demands, we seek politicians and governments that provide for us, give us benefits so that we can do what we desire, vice the tribal sense of contributing to and building the local community. We no longer focus on our duty to fellow citizens and our Dunbar numbered tribe, but our orientation is on what is our benefit, what are we entitled to and how can we systematically increase the reach of the benevolent government.Now, every bump in the night leads to a call for more government intervention, for a program to alleviate the issue, when the solution is found within a short walk of your house.Support the showwww.insidemycanoehead.ca

Carolyn Kendrick tells Taj about her relationship to music and coming to trust herself. • Come to Portugal for RISK!'s 15th Anniversary in May 2025: risk-show.com/portugal • Pitch us your story! risk-show.com/submissions • Support RISK! through Patreon at patreon.com/risk or make a one-time donation: paypal.me/riskshow • Get tickets to RISK! live shows: risk-show.com/live • Get the RISK! Book and shop for merch: risk-show.com/shop • Take our storytelling classes: thestorystudio.org • Hire Kevin Allison as a coach or get personalized videos: kevinallison.com To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Janice Kaplan is the guest of Tune Into Happiness, today's MIndfulness Mode episode. She is a journalist, TV producer, and the author of fifteen popular books, including the New York Times bestseller The Gratitude Diaries. Her upcoming book, What Your Body Knows About Happiness: How to Use Your Body to Change Your Mind, releasing January 7, 2025, explores the groundbreaking connection between body and mind in creating joy. A former editor-in-chief of Parade magazine, Janice has produced over thirty primetime TV specials and appeared frequently on national TV shows. With her signature humor and storytelling, she brings science to life, empowering readers to use their bodies to unlock creativity, positivity, and everyday happiness. Listen & Subscribe on: iTunes / Stitcher / Podbean / Overcast / Spotify Contact Info Website: www.JaniceKaplan.com Book: What Your Body Knows About Happiness: How to Use Your Body to Change Your Mind Most Influential Person Daniel Gilbert, Harvard Psychology Department Daniel Kahneman, nobel prize winner and behavioral psychologist Effect on Emotions I have been able to deal with my emotions differently as a result of my research.  That started with The Gratitude Diaries because I realize that we can control the way we feel about things. Classically, we can't control the things that happen but we can control how we deal with them. Thoughts on Breathing I don't personally have a breath-work practice but I know it can help enormously.  I was with some folks the other day who had two little kids, a 4-year-old and a 2-year-old. The kids were running around and the parents stopped the children and ask them to breathe in 1,2,3 and breathe out 1,2,3. The kids had obviously done this before. The 4-year-old said, no Daddy, we breathe in for 4 counts.   Suggested Resources Book: The Feeling of What Happens: Body and Emotion in the Making of Consciousness by Antonio Damasio Book: How Emotions Are Made: The Secret Life of the Brain Lisa Feldman Barrett Book: A Philosophy of Walking by Frederick Gros  App: n/a  Related Episodes Find Peace With 365 Days of Happiness; Jacqueline Pirtle Booster Shot of Happiness; Soren Russow The Future of Happiness With Amy Blankson

"I left my corporate job to dive in with the idea to start rapping and playing violin." -Zac Clejan Welcome to another exciting episode of the Turmeric & Tequila Podcast! I'm your host, Kristen Olson, and today, we're thrilled to have Zac Clejan, the incredible "trap violinist," join us. Zac's unique fusion of classical violin and hip-hop is making waves in the music scene. In this episode, Zac shares his inspiring journey from a tough childhood and strained family relationships to quitting his corporate job just before COVID to fully commit to his musical dreams. We'll discuss the importance of self-belief, persistence, and building a supportive community. Zac offers insights into his creative process, blending rap and violin, and discusses the essential business skills needed for independent artists to succeed. A special thanks to our sponsors—Lux Neuro, Declan James Watches, and Colorado Clownfish Swim School. So, grab your turmeric latte or favorite tea, and let's dive into this powerful episode! Time Stamps: 00:00 Classically trained musician combines hip hop violin. 03:24 Podcast emphasizes mental health, creative outlets' importance. 07:34 Self-education and embracing failure for growth. 12:45 Business skills crucial for creatives' success. 15:31 Success requires unseen hard work and mentorship. 17:52 Learning music independently through social media platforms. 20:53 Trust small community; ignore broader industry opinions. 23:03 Quit job pre-COVID, utilized support for music. 25:49 Writing driven by intense emotions and experiences. 30:24 Focus on your journey, avoid comparisons. 35:00 Developed unique style: violin and vocal hook. 36:05 Uniting communities through music, bridging exclusive gaps. 40:19 Two albums coming soon; check social links 44:36 Zach inspires entrepreneurs; a mentor through music. 45:44 Outro   Zac Clejan: Clejan is an American rapper, singer, songwriter and classically trained violinist from Atlanta, GA. Gaining notoriety for his uniquely blended style of music, He has appeared on the Kelly Clarkson Show, opened up for Busta Rhymes, Snoop Dogg, French Montana & Soulja Boy, all helping his social following grow to over 1.5 million under his handle @thetrapviolinist. He has released 75+ original songs to this date with millions of streams across platforms. https://clejan.com/ https://x.com/clejanmusic https://www.instagram.com/thetrapviolinist/ https://www.tiktok.com/@thetrapviolinist   Connect with T&T: IG: @TurmericTequila Facebook: @TurmericAndTequila Website: www.TurmericAndTequila.com Host: Kristen Olson IG: @Madonnashero Tik Tok: @Madonnashero Website: www.KOAlliance.com WATCH HERE   MORE LIKE THIS: https://youtu.be/ZCFQSpFoAgI?si=Erg8_2eH8uyEgYZF   https://youtu.be/piCU9JboWuY?si=qLdhFKCGdBzuAeuI  https://youtu.be/9Vs2JDzJJXk?si=dpjV31GDqTroUKWH

As many Jews deepen their sense of Jewish identity, Dr. Mijal Bitton joins the podcast to explore the significance of our Jewish heritage, texts, and peoplehood and what it means as we enter the Hanukkah season. Bitton is a sociologist, storyteller, podcast host, and Jewish advocate who also serves as the spiritual leader of the Downtown Minyan in Manhattan.  As one of the first Sacks Scholars, she helps young people reclaim and reimagine Jewish traditions. In this week's episode, Dr. Bitton discusses  Sephardic Jewry, Jewish peoplehood, academia, the needs of young Jews, and the realities of intergroup and interfaith after October 7. Resources: The Morality and Ethics of Global Jewish Advocacy: Lessons from Rabbi Lord Jonathan Sacks - AJC Advocacy Anywhere Jewish Unpacked - Wondering Jews podcast, with guest AJC CEO Ted Deutch Listen – AJC Podcasts: The Forgotten Exodus: with Hen Mazzig, Einat Admony, and more. People of the Pod:  The Next Chapter in Catholic-Jewish Relations What's Next for the Abraham Accords Under President Trump? Honoring Israel's Lone Soldiers This Thanksgiving: Celebrating Service and Sacrifice Away from Home The ICC Issues Arrest Warrants: What You Need to Know Follow People of the Pod on your favorite podcast app, and learn more at AJC.org/PeopleofthePod You can reach us at: peopleofthepod@ajc.org If you've appreciated this episode, please be sure to tell your friends, and rate and review us on Apple Podcasts or Spotify. __ Transcript of Conversation with Mijal Bitton: Manya Brachear Pashman:   Dr. Mijal Bitton is a sociologist, storyteller and Jewish advocate. As the spiritual leader of the Downtown Minyan in Manhattan and one of the first Sacks Scholars, she helps young people reclaim and reimagine Jewish traditions.  Michal is no stranger to our AJC audiences. Earlier this month, she delivered a powerful Advocacy Anywhere to commemorate Rabbi Lord Jonathan Sacks, for which the Sacks Scholars are, of course named.  And as co-host of Jewish Unpacked's podcast Wondering Jews, she and Jewish educator Noah Weisman explore questions we all ask about the Jewish experience, from the mundane to the miraculous. In fact, just recently, they interviewed AJC CEO Ted Deutch. The podcast has covered topics spanning from how summer camp shapes Jewish lives, how to constantly juggle joy and pain, the impact of the Jewish vote in the most recent election, and in turn, the impact of Trump's resulting victory on Jewish America. Mijal is with us now in our Midtown Manhattan studio to rehash a little of that, but also to discuss what led her to take on her many roles, including her newest project. Mijal, welcome to People of the Pod. Mijal Bitton:  Thank you, thank you for having me. Manya Brachear Pashman:   If you could please share with our listeners about your heritage, about your upbringing. You were born in Argentina, correct?  Mijal Bitton: I was born in Argentina. My father's family moved to Argentina from Morocco and Syria. My mother is from Spain. And part of what shaped my interest in Jews from the Middle East and North Africa, is that when we moved to America, we moved to a Persian Jewish community. So that was like my introduction to American Jews, this very tight knit Persian community in Long Island.  Eventually, I met my husband, who is a Syrian Jew, with Egyptian and Iraqi background, and I wrote my PhD on the Syrian Jewish community in Brooklyn, which all just shows you a little bit my fascination. It's not just an identity, it's a tradition that I draw from and that I believe can actually give us very powerful tools right now. Manya Brachear Pashman:  Now, is this a Syrian Jewish community from Aleppo or Damascus?  Mijal Bitton: Historically, there is a big difference. I would say that a lot of these communities, you can think of them as pre-immigration and then new settlement in America. Right now in America, it's one community. The differences between Aleppo and Damascus are not that pronounced, maybe like when you cook a little bit the recipe that you use, or slightly different songs that you might have, depending where your family is from. Manya Brachear Pashman:  You are, in fact, a visiting researcher at NYU, and you are the director of the National Study of the Sephardic and Mizrahi in the United States. What is that study all about? Mijal Bitton: Yeah. So when I wanted to do a PhD at NYU, which I did, on Syrian Jews, and I wanted to study Sephardic Jews, what I realized very quickly, and you might have seen this from your other podcast, is that there is very little good scholarship, good literature to explain to us who these Jews are. This is a problem, both in terms of historical research, and for me, I'm really interested in contemporary Jewish life.  There was a huge gap of not having resources to understand Sephardic Jews in the United States. So I had to do my PhD, kind of trying to reconstruct, you know, even, like the categories of study, how do we think about Jewish observance and really religiosity with Jews from the Middle East. So this study is an early attempt by early I mean, we hope it's the first of many studies to begin to tease out the main pillars of what we need to know to understand Sephardic and Mizrahi Jews roughly.  And again, we'll go into this more in the actual report, which will come out in a couple of months, roughly 10% of American Jews are Sephardic or Mizrahi, very similar to, let's say, the Orthodox Jewish population, the Russian-speaking Jewish population, but much less understood, much less studied. So it's an important first attempt to begin to lay out the foundations of knowledge. Manya Brachear Pashman:  So would you say that study is overdue?  Mijal Bitton: Yes, very much overdue. I think it's overdue for many reasons. One of them is that in the American Jewish community we've had for many years now, conversations around diversity, around inclusion and the like. And Sephardic Jews have not really been part of this conversation. Or let me say this with more precision, they have not been part of this conversation in terms that they would want to be part of this conversation. Maybe I'll be a little bit more explicit as to what I mean.  Many of the Jews that we've cited that I know tend to reflect more socially conservative, Middle Eastern forms of Jewish life, and these communities don't fit in very neatly in diversity efforts that tend to align with progressive understandings of diversity. So that means that there's been a real gap in how Sephardic Jews are included or not included in many spaces that are trying to be more inclusive. So we really believe that diversity is not easy, and that it begins with listening and understanding, who are the individuals and communities that we want to include.  Manya Brachear Pashman:  I mean, how does kind of a deeper and broader knowledge of one's Jewish identity, one's Jewish history, how does your deeper and broader knowledge of your identity and history help you be a better advocate? And how can it help others be better Jewish advocates? Mijal Bitton: That's a great question. So you know, you mentioned before that I started a weekly Jewish wisdom Substack. It's called Committed and I'll be grateful to share the link with everyone. The first piece that I wrote there on Genesis was actually about Jewish pride, and it was an idea that I had been thinking for a long time about, and it was that, especially since October 7, I have been in all of these spaces with people who are newly reawakened, energized, outraged about what's been happening. And they speak constantly about the need for Jewish pride, Jewish pride. We need more Jewish pride, more Jewish pride, more Jewish pride.  And on the one hand, I love that. I love that awakening. It resonates with me strongly. On the other hand, I had like this little voice whispering to me, because, as a sociologist, I've actually done research that talks about pride as something, I want to try to say this carefully, as something that is sometimes the last thing a group holds on to before assimilating fully.  So in very simplistic terms, if you think about Italian Americans or Irish Americans right over three or four generations in this country, they will slowly lose a lot of their communal elements. They will move away from their neighborhoods. They will stop only cooking Italian food. They will stop working in certain professions. But they will still have a little bit of that Irish pride in St Patrick's Day.  So I have been concerned when we speak about Jewish pride, that Jewish pride can be seen as unsustainable if we don't know what we are proud of. There is a world of a difference between someone who says there's something here, that seems really good, and I think I'm proud. I'm proud. And it's different that if you're standing there and you say, I am proud of a heritage spanning 1000s of years, I stand on the shoulders of giants. I am continuing a legacy of Jews who have survived persecutions, who've survived assimilation, who've survived living in different countries and in different times, and I am holding all of this when I stand up as a Jew. That, to me, is the kind of confident pride that can help us as advocates when we are facing challenges, because we are facing challenges and we're going to continue to face challenges. So we desperately need that sense of Jewish history, that sense of spiritual sustenance. We have to know what we are proud of, what we are fighting for. Manya Brachear Pashman:  You wrote a piece shortly after October 7, and it was titled, The Pain You're Feeling is Peoplehood. And it was incredibly powerful. It went viral. Because it so perfectly captured what so many Jews were feeling at that moment. And for those who haven't read it, can you share what led you to write it and kind of summarize it for our listeners. Mijal Bitton: I lead a community, I'm the spiritual leader of a community called the Downtown Minyan. And like many spiritual leaders and clergy on that Simchat Torah. I had to, you know, I'm not saying anything new. Here I was, I was heartbroken, reeling. I don't use a phone on Shabbat didn't always happening. My family in Israel, the reports that were coming in, I felt like my soul, my heart was being ripped. I think many of us felt this. And I had a Shul to run, and I had to figure out, like, what Jewish wisdom can I use right now? And it was very primal and instinctive.  There was a teaching that I had taught before because I thought it was important, but at that moment, it felt essential, and it just like, came out. I stood in front of my community who were in pain, and I wanted to give them names to explain what was happening. And I described, I use a very famous teaching by Rav Soloveichik, who speaks about who asked the question, can we still speak of ourselves as Jewish people, even with all of our diversity and differences and disagreements?  And it brings up a Talmudic question about, if you have a man of two heads, is this considered one person or two? And it's a complicated question, if you take it seriously, and he offers a gruesome test to figure this out. You pour boiling water on one head, and then you look at the other, and if it cries out in pain, it is one people. If it doesn't, it is two. The reason that this teaching was important for me to say, and I think the reason you said it went viral is because, you know. I haven't said this like this before, so I am expressing this now, thinking with you. I think for very long, for us Jews in America, we have been pushed and compelled to think of Judaism along Protestant religious terms.  What I mean by this, it's a faith, it's a set of beliefs, it's a value system. It has to fit in like some universalistic framework, and that pain that we felt on October 7 was different. It was a reminder that to be a Jew is to be part of a family. That it doesn't matter how different we are from each other, how much we disagree. When your relative is in pain, you cry with them. And it's almost like that pain, to me was like a way of saying we are reminded that we're part of a family. And there's something. I don't have the right words here. There's something almost to treasure about the pain, because it reminds us that we are connected to each other, committed to each other, responsible for each other.  And I think we all felt it, and it took away some of the layers of conditioning that many of us have had, to pretend like we aren't a family. That's what I think was one of the things that were so powerful about the tragedy that we all experienced. Manya Brachear Pashman:  Yeah, because we're so trained to be individuals, right, especially here in America, right, that individual spirit, and that's, that's not part of peoplehood. Or is it? I don't know. Maybe that's not the point.  Mijal Bitton: Yeah, listen, I think our tradition is amazing and complex, and there's strands of faith that brings up individualism and agency, but there's powerful strengths that talk about us as a family, as a collective, as a tribe, and there's powerful elements in our culture that have been pushing against that. And in many parts of our community, I think we drank the Kool Aid and we said we are not like, you know, that's backwards. That's not who we are anymore.  And then we were reminded that there's something there that we all felt was true. It existed before October 7, but I think October 7 kind of like woke it up. When I've shared this metaphor of the two headed men with people, many of them have offered an objection, and they've said, how awful is it for us to speak about who we are based on antisemitism? It shouldn't have to be like that. But, I mean, I would agree with that critique on theoretical terms. On sociological human terms, there is nothing that is more potent than having a shared enemy, a shared tragedy. Think about a family again, how tragedy brings us together.  So I think that unfortunately, the fact that there is still antisemitism vibrant in our societies and our streets has served to continue to reinforce that initial sense that we had after October 7. Of course, there are rifts. We can talk about debates that are happening. We are not as united as right after the tragedy. But, you know, I wrote a piece for CNN basically saying that the virulent anti semitism in the anti-Zionist movement is creating more Zionists. It's creating more Jewish solidarity. And it hasn't gone away. I am a religious woman. When I pray to God, I ask God that God should give us the challenge of having to remain connected in good times. I prefer that, but being that we don't have that right now, I do think that we have to double down on what our response is. Manya Brachear Pashman:  You wrote another piece for CNN that had to do with the anti-Israel protests on university campuses and the fear that it was inducing in so many Jewish young people, and the solidarity that was coming out of that. So with that in mind, one thing that the Jewish communal world is experiencing, we're certainly seeing it here at AJC, is an influx in involvement. Not just solidarity, but activism and advocacy, people who want to be more involved. Have you given any thought to this influx, and whether or not the infrastructure is in place here in America especially, to kind of sustain that, that level of involvement and activism.  Mijal Bitton: So one of the things that I've seen, and I'll be honest, that I'm still trying to understand it, but one of the things that I'm seeing is, there's, there's the thing called the organized Jewish community, okay? And it's a powerful ecosystem, you know, with lovers of power and influence. And I'm also privy, partially because of my work with young Jews, to a whole world of people who are wanting to be active, but who either don't have the access or the orientation to do so, you know, within the organized Jewish community And for me, part of what's still missing are the bridges between these different ecosystems. There's all of these people who are active on social media, right? The world of influencers, there's these groups of young Jews who are creating pop up Shabbat dinners, like all over the place, and like creating new clubs to celebrate Shabbat with each other and Jewish identity. And there is a lot of energy there. And what I'm trying to figure out is, I'm thinking of this as almost two powerful ecosystems, and I think that they would both be more powerful if they're in better conversation with each other.  So that, to me, again, it's a little bit abstract. I'm still thinking it through. I am a scholar in residence at the Maimonides Fund, and this is one of the questions that I have right now in this post-October 7 world: what would it mean to better bridge between these different ecosystems? Manya Brachear Pashman:  We just talked about the campus protests and the solidarity that they fuel, and we've also talked about the lack of research and scholarship out there about Jews in the Middle East and and North Africa and the diversity of the Jewish community. Do you think if young people had a better grasp of the thousands of years of history, of Jewish history in the Middle East, do you think that would shift the conversation at all, that education? And I don't mean obviously just within the Jewish community, I mean more broadly. Mijal Bitton: I mean, broadly speaking, yeah. So I would say two things I take to heart with my friend Haviv Retig Gur, who's a brilliant analyst. He speaks a lot about the fact that Jews, we don't know our own story. And I do think there is, like, huge lack of literacy in understanding that there were nearly 1 million Jews all across the Middle East and North Africa, and they left, fled, or were expelled in like massive Arab nationalist, anti-Zionist regimes that were propped up across the region. So I do think that for people to know these stories would be incredibly powerful.  I do want to note something, though, as someone who has been active in academia, I still have one foot there. I think that in many places, and we need to not be naive. In many places, people have vested interest in certain narratives, and they are emotionally attached to this narrative, and they have no incentive to change them, no matter how many counterfactuals you provide to them.  So there are definitely many parts in academia that want to think of the world as divided between the oppressors and the oppressed, and who want to think of Jews and Israel and Zionists as aligned with the oppressors, who they equate to Europeans and white and Westerners. And no matter how many counterfactuals you will give to them, they will find a way again, and I'm happy to explain this. They will find ways to make it fit into their narrative.  So we need a multi-pronged approach. One approach is to give the literacy to those who are seeking it as a way to have greater strength and intellectual tools at their disposal. Also, there's like a huge middle to convince, you know that can be moved. And when it comes to those ideologues, we have to battle their narratives. Manya Brachear Pashman:  In other words, offering that literacy to the Jewish community first, to those who actually want it, who are curious enough to want it, that's step one.  Mijal Bitton: Yeah, Jewish community, friends of the Jewish community, people who are intellectually honest and want to have a better discourse around Israel, the Middle East and current reality. Manya Brachear Pashman:  So Mijal, I am curious how your conversations have changed and evolved since October 7. Initially I wanted to ask you about interfaith dialog, but maybe intercultural dialog is a better way to put it. But did you have more intercultural dialog before October 7 or after October 7, or is your work really immersed in the Jewish community and Jewish dialog? Mijal Bitton: Yeah, so I would say like this: I think before October 7, I had spent many years focused on interfaith work. I think that the interfaith work was often anchored in more liberal and progressive spaces, and many of those efforts really imploded. And I think that I represent, because I've heard this from so many people who basically said, we've invested years into showing up for others and into relationships. And then if I can't get someone to say that–you don't need to like Israel, you don't need to like Netanyahu, but just that Hamas raping and murdering is wrong and evil–then what am I doing here? So I think that definitely, I have been affected by that, by seeing that.  And right now, I think we're in a place a year out when there is new energy in trying to figure out, okay, like, who are those people that we can still talk to, and they exist. And also I think that, and this is like work that is ongoing, there is a real sense that we need to re-examine the work that we were doing. Perhaps we were investing in the wrong interfaith relationships and spaces. Which doesn't mean interfaith work is bad, but maybe we need to invest in other parts of interfaith work. Manya Brachear Pashman:  Can you expand on that a little bit? Mijal Bitton: I mean, yeah, this is like, personal. I am not going to be spending time in interfaith work with people who give Hamas a pass. I'll just say this, you know, like that. And I think there's a lot for me. I am much more interested right now in pursuing relationships with socially conservative leaders of other faiths, that perhaps in the past, we wouldn't have been in the same tables around interfaith work and who have spoken up with clarity when it comes to defending Jews and speaking up against antisemitism.  This doesn't mean, again, I don't want to imply that we should walk away from spaces you said before, it's important to have people fighting in many different areas. I think the real question we have to ask ourselves is, what are the lines, that if they are crossed, we walk away? Because I think too many Jews, for too long, have stayed in spaces where our basic story, dignity and humanity, was trampled, and we accepted that price. And that is not something we can do anymore.  So we have to figure out, how do we reconfigure relationships? How do we stand up for ourselves in different ways? How do we, and I'll say this: in many places Jews showed up and agreed to, you know, like, pound their chest about, like, their white Jewish privilege as a price of entry into coalitions and relationships in ways that just were not honest. We need to fight all of this. Manya Brachear Pashman:  You recently hosted AJC CEO Ted Deutch on your podcast Wondering Jews, and I'm curious what you learned from that exchange with him, both on and off the air. Mijal Bitton: Yeah, it was wonderful. I co-host the podcast Wondering Jews with Noam  Weissman, and it was really nice. I mentioned this on that episode, but I have a very fond personal memory of my first encounter with Ted. It was the March in Washington. I was one of their earliest featured speakers at the March. You know, 300,000 people in person, many watching live. And I was very nervous. And I was like, pacing behind backstage. And I see Ted.  I've never met him before, but I had read about him. And when I read about him, I was very curious. I'm like, who leaves sitting Congress to go and work for the Jews? So I was already, fascinated by like, who would make this career switch? And then I saw him, and I don't know why, I turned to him, and I asked him if I could practice with him. And he literally had me practice my speech. I memorized it, and I practiced, and he gave me some feedback, and I changed some of the words, and his wife lent me a hostage tag necklace because I wanted to have one on stage. And it was early days, I didn't have one.  So my first encounter with him was that it felt like a very personal one, and that's what came across, I think, in the in the podcast, that Ted is this, you know, was a member of Congress, like runs AJC, but he just, he's so warm, and it is so obvious in everything that he says, that this is not like a job for him, but it is a passion and a life's mission. And the way that he spoke about just his love for the Jewish people, for spirituality, for what it means to stand up in the world, his hope and optimism. He speaks about relationships that you can insist on and make sure that you can have right now. It's very moving to find leaders who are running institutions and who themselves are able to embody a very powerful sense of conviction. We need more leaders like that. Manya Brachear Pashman:  So tell us about your newest project.  Mijal Bitton: Yeah, it's called Committed. That's the name of the Substack. I started it on Simchat Torah. I'm still tinkering with it. Like you know, how long it should be, the tone, this, that. I'm very lucky to have a lot of readers and students who eagerly give me feedback as to what works and what doesn't, which is lovely, because I love learning Torah with them. But really, as many conversations that I've had with people about anti semitism and advocacy and Zionism on campus, as many conversations that I've been having around like antisemitism and Israel and politics, I have been having the same number of conversations about Judaism and spirituality and the soul and what it means to be part of this magnificent tradition.  I have been taken aback that often in my my classes and lectures, it will end with people coming to me afterwards and wanting to speak about their Jewish journeys, what it means to raise Jewish children, what it means to learn Torah, if you didn't grow up learning Torah, and now you want to what it means to to know that we are souls with bodies, as opposed to bodies with souls, all of these things.  I have felt that it's really important to try to to have weekly touch points that we can have to ask big questions and to be able to address them using Jewish tradition. So I've in my Substack so far, I've explored, like I mentioned before, Jewish pride, what it means to have Jewish pride. I've explored what it means to have, using the stories of Abraham and Rebecca, what it means to, when the world is burning, to know that we have multiple modes of responses. One of them is to provide justice, put out the flame.  Another mode is to help those who have burn marks and to just show care to them and be with them in times of need. The one that I wrote that I think went the farthest. One was around sacrifice, the binding of Isaac, which I wrote about what it means to from America. Look at Israeli parents and know that they are raising children who are willing to sacrifice in a way that American children are just not being taught.  I use the story of Jacob and Esau, and I did a beautiful thought experiment. What would have happened if a Chabad emissary would have met the bad twin of Jacob? And there's all of this text that actually allow us to imagine that Esau could have become a leader of the Jewish people if he would have been shown the kind of love that Chabad emissaries give. So I think there's amazing ways to approach Jewish tradition and to use those as and use Jewish tradition as a way to ask the most critical questions about what it means to live as a Jew today.  Manya Brachear Pashman: I imagine you'll be lighting candles soon for Hanukkah. Any other special traditions? Mijal Bitton The one thing I would say that I love that we do in our Sephardic communities, we light a little bit differently. And this is a traditional way. There's some Sephardic Jews that have changed this a little bit, but traditionally we light one Hanukkiah (menorah) as a family. So in many Ashkenazic communities, each individual lights their own. Classically, in the Sephardic tradition, a family has one Hanukkiah, and we try to light it either by a window or, even better, outside. So my family, my parents, my siblings, they have a special Hanukkiah with glass panels, and we always light it outside the house, facing the streets in a very real way.  And I think that's an important symbol for us, what it means to insist on our lights in public spaces, what it means to fight for public spaces, and what it means, I would say . . . you know, Hanukkah has become such a commercialized holiday in America that, like lives alongside Christmas, and that feels good.  And it's become not just a watered down version of its original premise, but in many ways the opposite, because what the Maccabees did is they took on not just the Greek Empire in military terms. They took on the Greek Empire in cultural and spiritual terms, and they resisted assimilation with everything they had. So in a funny way, in America, to fit in, we've remade Hanukkah in terms that have been opposite in its original meaning.  And I think this last year asked us to reconsider what Hanukkah should look like, and what would it mean, you know, we shouldn't, I'm not saying we should be like the Maccabees exactly. You know, they're a complicated story as well. But what would it mean to make sure that we're not only lighting a light outside, but that we are expressing our Judaism in Jewish terms, even when it's a little bit uncomfortable for others.  Manya Brachear Pashman:  Mijal, thank you so much for joining us.  Mijal Bitton: Thank you for having me. Really great to be here. 

On today's episode of The Wholesome Fertility Podcast, Caryn Johnson of @_bondlife shares her personal journey through infertility, detailing her struggles with unexplained infertility and the eventual discovery of autoimmune issues affecting her reproductive health. She emphasizes the importance of understanding the immune system's role in fertility and the impact of lifestyle factors such as diet, stress, and environmental toxins. Caryn advocates for women to take charge of their health by educating themselves and seeking out supportive healthcare practitioners. She also discusses her supplement line, Bond, which aims to address these issues holistically.   Takeaways   Caryn's journey began with unexplained infertility. She experienced multiple failed IVF attempts. The immune system plays a crucial role in fertility. Many women with unexplained infertility have underlying immune issues. Stress and lifestyle factors significantly impact reproductive health. Gut health is linked to fertility and autoimmune conditions. Caryn's research led her to create a supplement line, Bond. Advocacy and education are essential for women facing infertility. Environmental toxins can affect fertility outcomes. Women should empower themselves with knowledge about their health.   Guest Bio:   Caryn Johnson is the Co-Founder and CEO of BOND, an innovative line of supplements reimagining hormone and reproductive health, inspired by her experience with infertility. The former Vital Proteins Chief Marketing Officer launched BOND in the Fall of 2023, fusing her professional expertise with her passion to help women take a more proactive and empowered approach to caring for their cycle and reproductive health.   In 2017, when trying to start a family, Caryn learned she was autoimmune infertile. What she discovered was a stark reality - the lack of open conversations and support for women facing similar struggles. The doctor's office often left much unsaid, and the information available was surprisingly scarce. Shocked by the limited support system in place, Caryn recognized the need for a change. She leaned on her industry knowledge and contacts to advocate for herself and uncover invaluable resources. Her personal journey became a catalyst for a larger mission to make her learnings accessible to women everywhere. It was this experience that led her to create BOND.    A natural born innovator, Caryn is disrupting the marketplace with this new line of products that offers women the opportunity to take control of their reproductive health before it's too late. BOND's proprietary formulations, designed to preserve fertility potential and lay the foundation for a healthier body, feature science-backed ingredients that work together to balance hormones, protect egg health, and provide cycle support. With BOND, Caryn aims to address women's health more holistically and encourage a more proactive conversation around reproductive wellness.    Caryn's career began in marketing and public relations where she worked with many notable beauty brands and PR firms before being recruited as the fifth employee at then startup, Vital Proteins. She was the first marketing hire at the organization and ultimately, became the company's Chief Marketing Officer leading the team through the brand's acquisition by Nestle Health Sciences. Following her tenure at Vital Proteins, Caryn took on the challenge of leading Owlet, a baby monitor company focused on preventing SIDS, where she served as Chief Marketing Officer and successfully guided the company through its initial public offering.   Caryn lives in Chicago with her husband and two children Elijah and Ruthie.    You can use coupon code THEWHOLESOME for 20% off all products. https://bond.life       For more information about Michelle, visit: www.michelleoravitz.com   The Wholesome FertilityFacebook group is where you can find free resources and support: https://www.facebook.com/groups/2149554308396504/   Check out Michelle's Latest Book: The Way of Fertility! https://www.michelleoravitz.com/thewayoffertility   Instagram: @thewholesomelotusfertility   Facebook: https://www.facebook.com/thewholesomelotus/     Transcript:   Michelle (00:00) Welcome to the podcast, Karin.   Caryn Johnson (00:02) Thank you. Thank you for having me.   Michelle (00:05) It's so nice to meet you. And I know that you do a lot of amazing work helping women I also know that you have your own story that you can share. And I would love to hear your story and really what got you inspired to do the work that you're doing.   Caryn Johnson (00:21) Yeah, absolutely. So I'm here to share really the start of how I got to where I am today. And that really is rooted in finding out that I couldn't get pregnant. So we can start there and then we can get into all of the details together. But my husband and I met when I was young, early 20s. And by the time we got married many years later, we were already   most right away to start having a family. There was a piece of me inside that knew that I was gonna have some sort of issue. I don't know, you already mentioned that you do visualizations to me before we started. So, you know, like I just had this feeling whether I manifested it for myself or not. I, you know, we did the full year of trying to get pregnant to no success and then went back to our doctor.   Michelle (01:03) Yeah, yeah.   Caryn Johnson (01:18) my typical OB-GYN and started the path of IUIs, did four IUIs, had beautiful eggs, each IUI, and reacted to the medicine quite well, but never got a positive from any of those. So we were recommended to move towards IVF. found a reproductive endocrinologist in Chicago, which is where I was located at the time.   started the path to IVF and went through the process of an egg retrieval. Ended up seeing similar to what we saw in the IUIs, which was that my reproductive system performed quite well. And I was able, they were able to retrieve just about 30 eggs from one retrieval, which is quite high, borderline too high, but.   just shows like the reaction to the medicine and the overall viability of my reproductive system. Of that, I had really normal odds and was able to bank close to 14, I believe, quality grade embryos. So I was really excited to move into implantation because at that point,   I just really thought like whatever was unexplained is just kind of, you know, over to the side now. you know, all these things are just working out in my favor. So this is gonna be, you know, it for me, which a lot of women I feel like go into IVF feeling like the IVF center is like the place where you get your baby, which isn't always true. So.   I started doing implantations and I started losing babies. Prior to that point, I had never even tested positive in any sort of like regard for a pregnancy test. And I wasn't one of those that, you know, jumped right off birth control, you know, to move into conception. I hadn't been on birth control for many, many, many, many years, you know, prior to this point. But the implantations started failing and   My doctor said, this embryo was only attached for two hours, maybe a couple of hours is what they said. I just thought, how on earth, like why on earth would something attach for just a couple of hours and then that be the situation where   It just doesn't work out from there. Like what is happening? And you know, got immediately, the immediate response was bad odds. You know, this happens, miscarriage happens. Just keep going. You know, one in four, in eight, you you get all the stats and there's definitely a piece of that when you're not working with really good quality embryos. But you know, I was, I knew that everything was genetically great. knew.   and had no reason to believe that my body wasn't in working order to, you know, produce a pregnancy. So I just started pushing harder and getting a little bit more more fearful of continuing down the path of losing babies because I just, it hit me so hard. Even the loss of two hours, I mean,   I just like, I've never felt sorrow like that. And I didn't, I just didn't feel like myself or really anyone should have to like continue down that path for like the sake of odds. So I started doing my own research and I was at the time experiencing some issues in my digestive system. I also now looking back had a definite cortisol issue.   which relates into the picture, but I was a CMO at Vital Proteins at the time, which is that blue tub collagen company. And so I had a high stress level and I knew that something was going on in my digestive system. This was, you know, 2016, 2015, 2016, 2017. So.   Michelle (05:39) yeah.   Caryn Johnson (05:58) almost prior to when we really started, you know, as a world, as a community talking about the microbiome and gut health. But I sought out a naturopath who ended up doing a blood panel on me and told me that I had, you know, hundreds of food sensitivities, which is a   a classic sign of gut dysbiosis, but at the time it wasn't translated back to like an issue in the microbiome. It was treated as like, yes, you have all of these, you have all of these issues with, you know, different foods, just avoid them. And that will be the solve versus, why do you have like, you know, why do you have a hundred things that you can't eat?   Michelle (06:42) Hmm.   Caryn Johnson (06:46) like watermelon seeds up to your typical gluten, et cetera. So I just started doing my own research online and I found a book called, Is My Body Baby Friendly? It's written by Dr. Alan Beer, who is now deceased, but it's over 700 pages of the science of how the immune system works with your reproductive system, your hormones, et cetera.   in order to effectively procreate or in order for conception and implantation to occur. And that's when I realized there was something greater going on in my body outside again of just my reproductive system that we just hadn't figured out yet. So I read the book Front to Back. It's a very science heavy book. So I had to do a lot of like   thinking about new terms and figuring and trying to remember what I was learning. At the end of the book, there was a recommendation at the time, there are more doctors now, but at the time for three doctors that practice this type of medicine, which is the field of reproductive immunology. And so,   Michelle (08:01) Mm-hmm.   Caryn Johnson (08:03) One of those doctors, Dr. Joanne Kwok-Kam of Rosalind Franklin ended up being in my backyard essentially 45 minutes away in the Chicago area. So I took that as a sign that I needed to call and get additional help above and beyond my RE who was doing the IVF. And I called over there and was immediately put on a six month wait list.   So proceeded with the next round of IVF because I was already on some hormones. So I was already going through the round. I had at that point only done my own research. So I wasn't really sure what was going on in my body or if I could believe what I had read because my doctors that were helping me with the IVF weren't really like saying that   They believed in the immunology side of things. They hadn't seen enough research, et cetera. So I wasn't really getting support on what I was researching. So it was around the holidays, October-ish, when I ended up calling into the clinic and I ended up getting a call right around   Thanksgiving that they had a cancellation and I got moved up on the wait list. So I ended up getting into the reproductive immunology clinic many months before they said I would two weeks before my next IVF transfer and that was just an awesome Hail Mary. They did a full ultrasound. So tip to toe thyroid, you know, your whole stomach area inside and outside.   And then they do the craziest blood panel that I've ever done. don't know how you can even draw that much blood, but vials and vials of blood to look at immune markers in addition to hormone markers, vitamin markers, and your typical blood panel. And they called me back 48 hours later and said, need to cancel this implantation. You have the highest level of antibodies that we've ever seen.   not that we've ever seen, but that we're able to track. So you're past like where the chart goes essentially. So if you proceed with your implantation, it's almost definitely gonna end in a miscarriage because your body is gonna fight it off. And at that point I was terrified because that was like the first real something's actually wrong with you that I had heard.   Michelle (10:21) wow.   Wow.   Caryn Johnson (10:50) Everything else was just unexplained, unexplained, unexplained. And I just went into shock. I didn't know what to do. I didn't know who to believe. You know, I had two sets of doctors saying different things. So I proceeded with the implantation and I ended up implanting both a boy and a girl embryo. And then   started treatment right away on my immune system through the reproductive immunologist. So what they did was they put me on a series of pretty intense medications to quiet my immune system. And then I did what is called IVIG, which are blood transfusions or infusions that essentially look   to wash your blood of the antibodies that are over protecting the immune system. So I went into this protocol and I ended up getting pregnant. It was positive right away. we saw, so the clinic ended up treating me one to three times a week with this IVIG infusion, which they're about two to three hours long based on, they're based on body weight.   Michelle (11:50) Mm-hmm.   Caryn Johnson (12:14) I was in their office, you know, at least one to two times a week, also for an ultrasound. So I knew by five weeks that both embryos had attached. you know, at that point, my immune markers were even more all over the place. We couldn't get my immune system to a stable level by any means. And I ended up losing the girl embryo at seven weeks.   her heartbeat slowed and then ultimately it stopped, which is one of the symptoms or issues when you have an autoimmune issue going into a pregnancy. So, you know, that was so sad and devastating and she was higher up in the womb than the boy embryo. So at that point,   It was pretty much 50-50 odds of if she was going to end up coming out and bringing him with her or if she was going to be what's called a vanishing twin, which is when your body reabsorbs the pregnancy for the sake of the other pregnancy, which is really the best case scenario because then you don't lose the other baby.   Michelle (13:18) my gosh.   Caryn Johnson (13:36) I was put on bed rest. This was the start of my bed rest between six and seven weeks, which continued until I gave birth, basically. I was able to go to work, but that was pretty much it. And I lived in fear that we were going to lose a little boy, but I ended up reabsorbing the girl embryo. So she never came out and we just really aggressively treated my immune system.   which held on until 34 weeks when I went into basically how the immune system works during the pregnancy is during the first trimester, there is more inflammation that can be in the body and then it has to subside for the second trimester to continue successfully and then your inflammation increases and that's   eventually causes or is part of why you go into labor. But my inflammation and my immune system increased really fast. my water broke early and I ended up having him, you know, early but he was healthy because some of the immune medications included steroids. So he was a little bit bigger than, you know, your typical   34, 35 weaker. But I was able to carry my son and that really started my story of what the heck happened and why is autoimmunity so under researched when it comes to your reproduction and your fertility chances and how can I actually do more now that I have my children here.   Michelle (15:06) Mm-hmm.   Mm-hmm.   Mm-hmm.   Caryn Johnson (15:33) to support other women so they don't have to go through this amount of trauma, right? But also this amount of like research and advocacy for themselves because at the end of the day, like we just can't expect that from everyone and we shouldn't. We should be able to support. Yeah, so I'll take a breath there.   Michelle (15:40) Mm-hmm.   Yeah.   Wow, that's incredible story. And I mean, it's it's mind boggling, you know, that, nobody really talks about something that is so prevalent. And I do see that a lot, actually. And it could be the reason why you have unexplained infertility or why transfers don't work. And I speak to Amy Ralph, Amy Ralph, she's a   Caryn Johnson (16:19) Yeah.   Michelle (16:20) she does the same thing, Chinese medicine. And she talks about this a lot. She says, if you miscarry or you have repeated transfer failures with a good embryo and your doctor doesn't look into like what your lining is doing and how your immune system is working, then go to a different doctor because it's so important to look into that because you could spend so much time.   and you can spend so much money and just so many precious years going through so much loss for something that could be treated but can also be prevented. So I'd love to actually get your input on what you've discovered and how the gut relates to it but maybe other things that you've noticed or learned for the listeners.   Caryn Johnson (16:59) Absolutely.   Yeah, absolutely. And I think what you're saying is just incredibly important. Like the immune system, I feel like is the secret starting point to a lot of issues. And what's happening in medicine right now is a lot of women are walking away with an unexplained infertility diagnosis, but they're accepting that as a diagnosis, right? When it's not, it's just, it's not an answer.   And if you look underneath kind of that answer, you see a lot of crazy statistics, such as over 65 % of women who have unexplained infertility actually have an issue in their immune system. And then similarly over 60 % have an issue in their metabolic system. So blood sugar, insulin, know, early signs of PCOS, et cetera. And then.   Michelle (18:05) You   Caryn Johnson (18:10) When you look, you see that there are deep, deep nutrient deficiencies happening in this group of women as well. So you're looking at vitamin D deficiencies, vitamin B deficiencies, magnesium, omegas. All of these start with modulations that occur in the immune system as well. So when you think about it on a deeper level and from the research that I've done,   Michelle (18:23) Mm-hmm.   Mm-hmm, yeah.   Caryn Johnson (18:39) you're looking at something that's happened to you before it's affecting your hormones and triggering one of these other issues in your reproductive system. So like for instance, not only do I have, you know, autoimmune infertility, I do carry PCOS and adenomyosis as well. And for me, and based on the research that I've done, those are secondary factors.   to my immune system modulating and creating an overly inflammatory environment in my body, which then produced those issues. So we're not going up far enough in the chain of our bodies as to understanding our full systems. And again, it kind of goes back to like what's happening in medicine, which is that our doctors are   Classically trained in our reproductive organs, right? So they know our uterus they know our ovaries they understand how those work, but we need to get into you know, a new phase where we have Practitioners that understand how all of the systems are working together in our body Including our immune system and our endocrine system because they do have such a big and almost starting impact   Michelle (19:57) Mm-hmm. Yeah.   Caryn Johnson (20:07) on what's happening with our fertility.   Michelle (20:10) yeah, I completely agree. And I also I'm wondering, like, what have you seen? Because I think that when you talked about the food sensitivities, you were saying that it's okay, I'm allergic to so many things, or I'm sensitive to so many things, but why? So like, what are the things that you've seen that cause it to begin with?   Caryn Johnson (20:28) Yeah.   Yeah. So there are a couple of things that I see as a starting factors. One is overall stress. So if you can't keep your stress in check, you can't keep your cortisol levels in check, then your adrenal function will not perform in the rest of your hormones will not function correctly, which then trickles into some of these other problems. and then you get into other factors like what you're putting in your body.   the nutrition that you have or you don't have. They're saying the American diet is still between 60 and 80 % processed food. So we're putting still mostly junk into our systems that's modulating and creating these environments that we don't want. Number three is dysbiosis of the gut, right? Which is a huge factor in   Michelle (21:13) Mm-hmm.   Yeah.   Caryn Johnson (21:31) overall well-being and then your chances at fertility because what happens is that if your gut is in dysbiosis, your mucosal lining is disrupted and all of the toxins that are supposed to be in this like, think of it like pipe in your body, piped to get to the outside are now permeating that pipe and moving into your system and causing again, these major inflammation issues.   these, this uproar of immune response that is hard to counteract. You know, once you have that level of bacteria and then toxins that are entering the bloodstream. And then the last kind of reason that you would be kind of in this situation is just based on what's going on in your environment. So are you living in a city, you know,   that a lot of people in Detroit, for instance, there's a bigger rate of infertility there versus, you know, your non-city residents. It's also based on the toxins that enter your home. So are you getting rid of your plastics? Are you looking at the cleaning supplies you're using, the makeup you're putting on your face? It seems simple, but this toxic overload, again,   Michelle (22:52) Mm-hmm.   Caryn Johnson (22:55) creates this inflammatory response, which modulates your immune system. So those are really the four categories that kind of put you in this place. And then it kind of gets into epigenetics, which is like, you know, you've created this new world for yourself that your body has become. And, you know, is it going to be like that or are you going to be able to get yourself out of it?   Michelle (23:23) Yeah. my God. It's so important and it's true. We hear all the different factors and actually those toxins and the endocrine disruptors can be found in food, I mean, through pesticides and that can also impact your gut dysbiosis. so it's just, it's like an entangled web and it really is like a reflection of how we're living today and what's allowed in this country, which   Caryn Johnson (23:38) Yeah.   Yeah.   Michelle (23:50) I'm starting to get more and more frustrated with, you know, the fact that other countries are protecting their citizens more from chemicals and pesticides and things that are harming not only our health and chronic disease, also future. it's, it's unbelievable. And for that reason, I often tell people just go gluten free. It's not that.   Caryn Johnson (23:58) Yeah.   Gosh, get me started on glyphosate. It's so sad.   Mm-hmm.   Michelle (24:16) It's not that wheat is bad. And actually, as a matter of fact, a lot of people don't have those same responses if they go to Spain or Italy, even though it's not considered GMO, they have genetically modified it over the years. So there's so many aspects. So sometimes I'm just like, just remove it, And I see people feeling a lot better.   Caryn Johnson (24:26) Right.   Yeah.   Michelle (24:41) just from that, and especially with autoimmune conditions, actually that like going gluten free can really help. That's what I've seen.   Caryn Johnson (24:50) Yeah, no, definitely. It's just our food source is really sad. And it's just, it's so hard to pinpoint at the end of the day because no one really has the exact answer. But I just like, you see the data, like women who are eating on a Mediterranean diet have a lower risk of endometriosis.   Michelle (24:55) Yeah.   Mm-hmm.   Caryn Johnson (25:15) women who have like vitamin sources through green leafy vegetables don't have as much PMS. So like the correlations are there. It's just like, how do we get people to make better decisions for their body and understand like, don't be me, don't make bad decisions and then get into a position where you can't have the life that you wanted or dreamed of, or you have to fight so hard for it because   Michelle (25:16) Right.   Yes.   Mm-hmm.   Caryn Johnson (25:43) of choices you made earlier in your life from lack of knowledge, you know?   Michelle (25:47) Right. Yeah, totally. And then I also look at the nervous system, which is what you're, I feel like it's really linked to the cortisol issue, like the high stress, because we're constantly being bombarded with too much information. Really, I think too much information that our nervous system is able to translate. And I think that takes a trickle down effect into our bodies. I'm very big on like mind body because of that, you know, like that, that's one aspect, but of course, I mean, there's so many   Caryn Johnson (26:02) Mm-hmm.   Yeah.   Michelle (26:16) Like I said, it's like a web and every single piece matters. And that's what you were talking about before with medicine, looking at the body as a whole, as a functioning system, rather than just one part.   Caryn Johnson (26:21) you   Right, right. And just going back to your comment on cortisol, you know, a lot of it does start with cortisol because if you put yourself into too high of a cortisol state, your body doesn't produce enough hormones. It basically triggers all of your other hormones to act inappropriately. It goes into your progesterone receptor.   Michelle (27:00) Mm-hmm. Yeah.   Caryn Johnson (27:00) pretends it's progesterone and then it goes on your thyroid and says slow down, slow down. Your body doesn't have enough energy for this and your thyroid slows. So it's really like easy to dismiss like, yeah, I'm so stressed but I don't have to be stressed today and to understanding like if your body is in a constant state of stress, like the impact it can truly have on your system and on your hormones because   Michelle (27:27) Mm-hmm.   Caryn Johnson (27:30) I guess also people think of like cortisol is like over here and then estrogen and progesterone as like over here because they work through different axes of the body, right? But it's all related because if you knock one off, you're messing with the others. So I just, I wish people ultimately would understand that cortisol is a huge starting factor to their fertility journey as well.   Michelle (27:38) Mm-hmm.   Right. Yes.   Caryn Johnson (27:57) and to a hormone journey if they're not on the road to fertility.   Michelle (28:02) Yes, because ultimately the body's always going to favor survival. And when you're in high cortisol, your body's basically or something is signaling your body to let it know it's not safe. So when you're constantly in this state of feeling unsafe, your body's going to worry about other things and put off other factors that it would normally pay attention to when you do feel safe.   Caryn Johnson (28:08) Yeah.   Right.   Michelle (28:32) And being in this chronically is just not conducive to high vitality period.   Caryn Johnson (28:32) Right.   Yeah, I feel like at least we're in a better state of mind, like as a world where, you know, 10 years ago it was chic and cool to be like chronically stressed and like drinking like three cups of coffee in the morning and like running yourself ragged. Like I feel like everyone understands a little bit more that they shouldn't. It's just about like knowing your body and actually being able to say to yourself like, no, this isn't how I should.   Michelle (28:52) It's true. Yeah, that's a good point. Yeah.   Caryn Johnson (29:09) be feeling. This isn't how I want to keep stress or maintain like my day-to-day life.   Michelle (29:17) No doubt that we are getting educated like never before. like, it's, it's one of those things that when like the information comes out and we start to open our eyes, it's painful because we're realizing things that are not working. However, even though it's painful, it's actually helping us in the long run. And it's kind of like the, blessing and the curse of social media and all of the technology, but the blessing is information.   Caryn Johnson (29:28) Right.   Yeah.   Michelle (29:45) that is very important for us to know it's important for us to receive. So that aspect of it is really important. And then talk to us about your supplement product bond. And I know that you created that based on really your own frustration and it's become your baby. And I want to know what specifically or how does that address autoimmunity conditions for people who are going through that or?   Caryn Johnson (30:03) Yeah.   Michelle (30:14) least thinking maybe to look into their immunity in regards to their fertility, listening to this.   Caryn Johnson (30:21) Yeah, absolutely. So I launched Bond just about a year ago. I concepted it. took a year prior to that from concept to launch.   So really it started in the world of advocacy for me. I was just really looking to help other women getting involved in some Facebook groups, some communities. you know, there's not a lot of knowledge, a lot of people talking about this yet. There certainly wasn't, you know, even just a few years ago. so I, I took a speaking opportunity in Detroit and   I went to Wayne State University, which is where they do a lot of the research for autoimmune infertility. the main head of that clinic asked me to come and speak to the researchers because they do all of this research and it's isolated into their facility. They don't actually see the impact of what's going on with women who are going through this.   Michelle (31:24) Mm-hmm.   Caryn Johnson (31:25) so I got to share my story and, you know, had a really nice day there learning and seeing their facility, their lab, what's going on. And on the drive home is really when it clicked for me that there's a lack of, or there's a gap in what's going on research wise and, know, what's being discussed and what's being carried out and brought to.   the consumer or the public's attention. And I just felt like if I didn't take a larger stand to do something bigger to help women, that we'd be many, many more years behind even. So I went back to my house in Chicago, sat in my basement and did just clinical research for months. And I logged over 300 clinical studies, all centered around   the immune system and how it relates to hormones to the reproductive system and built my thinking for original skews, which were, which are daily balance, which is our best seller conception boost, vitality, and cycle care on this thinking first. so it really started with research before it was brought forward to healthcare practitioners and then formulated out.   And a lot of the research that went into each of the products is above and beyond supporting the reproductive organs. So when you look at daily balance as a whole, it has 15 vitamins and nutrients in it. And a lot of those vitamins and nutrients were chosen to not only support hormone balance, but to take that up a level and to support the immune system as it relates to being a predecessor to hormone balance. So   adding a vitamin D, which is a huge hormone regulator, putting fiber, five grams of it into a supplement so that women are potentially protecting their gut lining better and producing those short chain fatty acids that are going to protect their gut in a way that just probiotics don't. Adding in a probiotic blend that   we studied as being healthy strains, or not healthy strains, but strains from healthy fertile women. So really focusing on these immune factors and how they pull into the world of fertility. But to the public now, you know, almost simplifying that message and making it more of like the underlying theme because we're still not necessarily totally there.   so the ingredients exists in these formulas with so much thinking and thought as it relates to the whole body. and then the formulas come out and, they're focused on hormone balance, right? As well as we have a conception product, and then we have our cycle care product, which is focused on, PMS support. So PMS, symptom alleviation, and then hormone detoxification.   Michelle (34:16) Mm-hmm.   Caryn Johnson (34:44) So they all have an immune angle, also address a hormonal need.  And the other great thing too is that you can shop at a discount as a special thanks for listening to us here. You can head over to the link. We'll link it here with this podcast episode and use the code, the wholesome to get 20 % off your order.     Michelle (34:54) Awesome. And do you have information on your site, just like support for people wanting to learn more?   Caryn Johnson (35:00) Yeah.   Yeah, absolutely. we're starting to add more and more to our site. I wrote a white paper on how the microbiome affects fertility that you can download off of our website as well to get more information. And yeah, we share a lot on social too with, you know, article connections there. So that's another great way to keep up with kind of like up and coming research that we're seeing.   Michelle (35:32) Mm-hmm.   Caryn Johnson (35:33) But yeah, I would say too, just going back to one other thing you mentioned earlier on the, on the doctor front, the best thing to do as a consumer, like when you're hitting these issues is to bring the articles in and show them to your doctor and choose advocacy for yourself. Because I found that the response from them is far greater when you have data in your hands as to why you want to.   Michelle (35:51) Mm-hmm.   Yeah.   Caryn Johnson (36:03) add a supplement, think about a different form of medication, think about a different program that might make sense for your system. So I would say, you know, that is as important as ever. And, you know, what we try to do more and more is link that PIMD article, like when we post something so that you can find the actual source and see for yourself, you know?   Michelle (36:24) Mm-hmm. Yeah.   Caryn Johnson (36:31) read the information and make smart decisions.   Michelle (36:31) Mm-hmm.   I love that. That's great. I'm all about empowerment. think that we need a lot of that now. So this is great information. I really appreciate you sharing your story for people listening. And for people who want to find you and learn more, how can they find you?   Caryn Johnson (36:41) Yeah.   Thank   Sure, so our website is bond.life. Our Instagram is underscore bond life and we're, you know, a newer company. I'm still really involved on our social. So we love to take DMs and interact with people one-on-one that way. If you have any questions or want to get into, you know, what you might be experiencing and what our different products are, like we're happy to get into it with you and.   I will say for anyone that wants to shop on bond on our website, absolutely love to support you. And again, really the place to start with, with us is our daily balance product. has the baseline of nutritionals you need to support your   nutrients stores, your hormonal balance, and of course, your immune system. that is our purple bag on the website there. But Michelle, thank you so much for having me. I really appreciate this opportunity.   Michelle (37:57) Yeah, it was great having you on and having this conversation, which I feel like is so important because it is kind of like the big question mark that a lot of people are facing when they're trying to conceive. So thank you so much for coming on.   Caryn Johnson (38:09) Yeah, you're welcome.        

Can anyone make Malört, the controversial Chicago wormwood liqueur, taste good? Classically a shot you have unsuspecting Chicago visitors try, maybe paired with an Old Style for a Chicago handshake, Malört has been described as tasting like bug spray or gasoline. Lando walks us through some of the history of the company, before Andy and Mucci make some cocktails to try to see if they can make Malört taste good (or hide its bite a little bit). Andy has the guys try his own concoction, Andy's Delight (you heard it here first!) and Mucci cribs from Wicker Park speakeasy The Violet Hour. Who made the best cocktail? And do you have any Malört cocktails you think work?OTR Theme by Lando and Mucci. Other music: “Drum fill 2” and “Drum fill 5” by lewk on freesound.org.Follow us on our socials:IG: @otr_debateFB: @otrdebateor on YouTube! You can also email topics you think we should cover at OTRdebate@gmail.com!

Self-Aware LeadershipThe self-aware leadership sounds a bit like an oxymoron.You know what your intentions are when you do what you do and say what you say. So of course you're self-aware of yourself.BUT, are you really aware of all that you need to stay on top of to flawlessly execute your business strategy?Ooh, maybe not, and you wouldn't be alone. As today's guest, Robert Courser, author of Line of Sight: The Five Keys for Strategic Execution in an Age of Uncertainty, explains.What You'll Discover About Self-Aware Leadership:* The missing piece of self-aware leadership* How employee surveys contribute to self-aware leadership* How self-aware leadership lets you work "on" your business, not just "in" your business* Why self-aware leadership is essential for strategy alignment and execution* And much moreGuest: Robert Courser Robert Courser is a CEO advisor who has been helping small and medium-sized enterprises scale up for the past twenty years.In his book, “Line of Sight: The Five Keys for Strategic Execution In An Age of Uncertainty,” Robert draws on stories and anecdotes from his clients to share the simple tools and insights that help free up the growth potential of leaders and their companies.Classically trained as a culinary chef, Robert knows about delivering excellence in a high-pressure environment.In his inimitable, no-nonsense voice, Robert emphasizes the importance of internal alignment, of having resources in the right place at the right time, and of self-aware leadership to execute flawlessly.Related Resources:If you liked this interview, you might also enjoy our other Risk Management episodes.Contact Robert and connect with him on LinkedIn, Facebook, X (Twitter), and Instagram.Also visit Line of Sight.Join, Rate and Review:Rating and reviewing the show helps us grow our audience and allows us to bring you more of the rich information you need to succeed from our high powered guests. Leave a review at Lovethepodcast.com/BusinessConfidential.

Seasonal baking opens up exciting possibilities for commercial bakers to captivate customers, drive sales, and maintain a competitive edge. Tailoring your bakery's offerings to each season keeps your bakery both relevant and irresistible. Of course, crafting these seasonal delights (https://bakerpedia.com/festive-bakes-and-seasonal-treats/) demands more than creativity. it calls for technical skill in formulation, precise processing, and rigorous quality control to ensure each treat is perfectly executed. In this episode of BAKED in Science, host Mark Floerke is joined by three other baking industry professionals to discuss a baker to baker approach to seasonal baking. Richard Charpentier has over 35 years of extensive bakery experience in snacks and breads. Classically trained as a French baker and Certified Master Baker, he has gone on to include bakery science, grain milling and food history in his repertoire. He is currently the CEO of Baking Innovation (https://baking-innovation.com), finding practical uses for emerging innovations and technologies. Denise Stemmler is a Technical Sales Representative at Bakers And Us (http://www.bakersandus.ca/en/). Bakers & Us is a full service wholesale distribution expert, servicing the bakery and pastry industries of the Greater Toronto Area. Peter Jacobs is a highly skilled RBA Certified Master Baker with over 40 years of baking experience. He uses his experience in the bakery and food production industry at his company, The Bakers Workshop (https://thebakersworkshop.ca), to consult clients in product development, production-line application, economic production efficiencies, formula development, and mentoring recruits. The Change of Seasons in the Bakery Some topics covered include: Bakery preparation for the holidays Leveraging current technology Ingredient cost considerations for seasonal baking Learning from other bakers Baking regulation and certification Artisanal techniques in seasonal baking This podcast is brought to you by: Enzyme Innovation Enzyme Innovation can help you extend shelf-life and prolong softness in your baked goods with SEBake Fresh Ultra™, Enzyme Innovation's proven, high-performing Maltogenic Amylase. Call (909) 203-4620 or visit enzymeinnovation.com to learn more!

Dr. Ryan Augustin and Dr. Jason Luke discuss neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, promising new TIL therapy for advanced melanoma, and the emerging role of CD3 engagers in treatment strategies. TRANSCRIPT Dr. Ryan Augustin: Hello, I'm Dr. Ryan Augustin, your guest host of the ASCO Daily News Podcast today. I'm a medical oncology fellow at Mayo Clinic in Rochester, Minnesota. Joining me today is Dr. Jason Luke, an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center. I had the privilege of working as a postdoc in Jason's translational bioinformatics lab, where we investigated mechanisms of resistance to immunotherapy in melanoma and other cancers.  Today, we'll be discussing 3 important topics, including neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, the impact and practical considerations for incorporating TIL therapy into melanoma, and the current and future use of CD3 engagers in both uveal and cutaneous melanoma.  You'll find our full disclosures in the transcript of this episode.  Jason, it's great to have this opportunity to speak with you today. Dr. Jason Luke: Absolutely. Thanks, Ryan. It's great to see you. Dr. Ryan Augustin: So, to kick things off, Jason, we, of course, have seen tremendous advances in cancer immunotherapy, not only in metastatic disease but also the perioperative setting. Recent data have shown that the use of neoadjuvant therapy can provide not only critical prognostic information but can also help individualize post-resection treatment strategies and potentially even eliminate adjuvant therapy altogether in patients who achieve a pathologic, complete response. This signifies a conceptual shift in oncology with the goal of curing patients with immunotherapy. In triple-negative breast cancer, the KEYNOTE-522 regimen with pembrolizumab is standard of care. In non-small cell lung cancer, there are now four FDA approved chemo-IO regimens in both the neoadjuvant and perioperative settings. And, of course, in melanoma, starting with SWOG S1801 utilizing pembro mono therapy, and now with combined CTLA-4 PD-1 blockade based on results from the NADINA trial, neoadjuvant IO is the new standard of care in high-risk, resectable melanoma. It's important to highlight this because whereas other tumor types have more mature multidisciplinary care, for example, patients with breast cancer are reviewed by the whole team in every center, and every patient with lung cancer certainly benefits from multidisciplinary care conferences, that's not always the case with melanoma, given the relative frequency of cases compared to other tumor types.  Jason, would you say that we have now moved into an era where the integration of a multidisciplinary team and melanoma needs to be prioritized. And why is it important to have multidisciplinary team coordination from the onset of a patient's diagnosis? Dr. Jason Luke: Well, I think those are great questions, Ryan, and I think they really speak to the movement in our field and the great success that we've had integrating systemic therapy, particularly immunotherapy, into our treatment paradigms. And so, before answering your question directly, I would add even a little bit more color, which is to note that over the last few years, we've additionally seen the development of adjuvant therapy into stages of melanoma that, historically speaking, were considered low-risk, and medical oncologists might not even see the patient. To that, I'm speaking specifically about the stage 2B and 2C approvals for adjuvant anti-PD-1 with pembrolizumab or nivolumab. So this has been an emerging complication.  Classically, patients are diagnosed with melanoma by either their primary care doctor or a dermatologist. Again, classically, the next step was referral to a surgeon who had removed the primary lesion, with discussion around nodal evaluation as well. And that paradigm has really changed now, where I think integration of medical oncology input early on in the evaluation of the appropriate treatment plan for patients with melanoma is quite a pressing issue now, both because we have FDA approvals for therapeutics that can reduce risk of recurrence, and whether or not to pursue those makes a big difference to the patient for discussion early on.  And, moreover, the use of systemic therapies now, prior to surgery, of course, then, of course, requires the involvement of medical oncology. And just for an emphasis point on this, it's classically the case, for good reason, that surgeons complete their surgery and then feel confident to tell the patient, “Well, we got it all, and you're just in really good shape.” And while I understand where that's coming from, that often leaves aside the risk of recurrence. So you can have the most perfect surgery in the world and yet still be at very high risk of recurrence. And so it's commonly the case that we get patients referred to us after surgery who think they're just in totally good shape, quite surprised to find out that, in fact, they might have a 20% to 50% risk of recurrence. And so that's where this multidisciplinary integration for patient management really does make a big difference.  And so I would really emphasize the point you were making before, which is that we need multidisciplinary teams of med onc with derm, with surgery early on, to discuss “What are the treatment plans going to be for patients?” And that's true for neoadjuvant therapy, so, for palpable stage 3, where we might give checkpoint inhibitors or combinations before surgery. But it's true even in any reasonably high-risk melanoma, and I would argue in that state, anything more than stage 1 should be discussed as a group, because that communication strategy with the patient is so important from first principles, so that they have an expectation of what it's going to look like as they are followed out over time. And so we're emphasizing this point because I think it's mostly the case at most hospitals that there isn't a cutaneous oncology disease management meeting, and I think there needs to be.  It's important to point out that usually the surgeons that do this kind of surgery are actually either the GI surgeons who do colon cancer or the breast surgeons. And so, given that melanoma, it's not the most common kind of cancer, it could easily be integrated into the existing disease review groups to review these cases. And I think that's the point we really want to emphasize now. I think we're not going to belabor the data so much, but there are enormous advantages to either perioperative or adjuvant systemic therapy in melanoma. We're talking about risk reduction of more than 50%, 50-75% risk reduction. It's essential that we make sure we optimally offer that to patients. And, of course, patients will choose what they think is best for their care. But we need to message to them in a way that they can understand what the risks and benefits of those treatments are and then are well set up to understand what that treatment might look like and what their expectations would be out over time.  So I think this is a great art of medicine place to start. Instead of belaboring just the details of the trial to say, let's think about how we take care of our patients and how we communicate with them on first principles so that we can make the most out of the treatments that we do have available. Dr. Ryan Augustin: That's great, Jason. Very insightful points. Thank you.  So, shifting gears now, I'd also like to ask you a little bit about TIL therapy in melanoma. So our listeners will be aware that TIL is a promising new approach for treating advanced melanoma and leverages the power of a patient's cytotoxic T cells to attack cancer cells. While we've known about the potential of this therapy for some time, based on pioneering work at the NCI, this therapy is now FDA approved under the brand AMTAGVI (Lifileucel) from Iovance Biotherapeutics, making it the first cellular therapy to be approved for a solid tumor. Now, I know TIL therapy has been administered at your institution, Jason, for several years now, under trial status primarily for uveal melanoma using an in-house processing. But for many cancer centers, the only experience with cellular therapy has come under the domain of malignant hematology with CAR T administration. At our institution, for example, we have only recently started administering TIL therapy for melanoma, which has required a tremendous multidisciplinary effort among outpatient oncology, critical care, and an inpatient hematology service that has expertise in cytokine release syndrome.  Jason, where do you see TIL therapy fitting into the metastatic space? Which patients do you think are truly candidates for this intensive therapy? And what other practical or logistical considerations do you think we should keep in mind moving forward? Dr. Jason Luke: Well, thanks for raising this. I think the approval of lifileucel, which is the scientific name for the TIL product that's on the market now. It really is a shift, a landscape shift in oncology, and we're starting in melanoma again, as seems to be commonly the case in drug development. But it's really important to understand that this is a conceptually different kind of treatment, and therefore, it does require different considerations. Starting first with data and then actualization, maybe secondarily, when we see across the accelerated approval package that led to this being available, we quote patients that the response rate is likely in the range of 30%, maybe slightly lower than that, but a meaningful 25% to 30% response rate, and that most of those patients that do have response, it seems to be quite durable, meaning patients have been followed up to four years, and almost all the responders are still in response. And that's a really powerful thing to be able to tell a patient, particularly if the patient has already proceeded through multiple lines of prior standard therapy. So this is a very, very promising therapy.  Now, it is a complicated therapy as well. And so you highlighted that to do this, you have to have a tumor that's amenable for resection, a multidisciplinary team that has done a surgery to remove the tumor, sent it off to the company. They then need to process the TIL out of the tumor and then build them up into a personalized cell product, bring it back, you have to lympho-deplete the patient, re-introduce this TIL. So this is a process that, in the standard of care setting under best circumstances, takes roughly six weeks. So how to get that done in a timely fashion, I think, is evolving within our paradigms. But I think it is very important for people who practice in settings where this isn't already available to realize that referring patients for this should be a strong consideration. And thinking about how you could build your multidisciplinary team in a way to be able to facilitate this process, I think is going to be important, because this concept of TIL is relevant to other solid tumors as well. It's not approved yet in others, but we kind of assume eventually it probably will be. And so I think, thinking through this, how could it work, how do you refer patients is very important.  Now, coming back to the science, who should we treat with this? Well, of course, it's now an air quotes “standard of care option”, so really it ought to be available to anybody. I will note that currently, the capacity across the country to make these products is not really adequate to treat all the patients that we'd want. But who would we optimally want to treat, of course, would be people who have retained a good performance status after first line therapy, people who have tumors that are easily removable and who have not manifested a really rapid disease progression course, because then, of course, that six-week timeline probably doesn't make sense. The other really interesting data point out of the clinical trials so far is it has looked like the patients who got the least amount of benefit from anti-PD-1 immunotherapy, in other words, who progressed immediately without any kind of sustained response, those patients seem to have the best response to TILs, and that's actually sort of a great biomarker. So, this drug works the best for the population of patients where checkpoint inhibitors were not effective. And so as you think about who those patients might be in your practice, as you're listening, I think prioritizing it for primary progression on anti PD-1, again and giving it ahead thought about how would you get the patient through this process or referred to this process very quickly is really important because that lag time is a problem. Patients who have melanoma tend to progress reasonably quickly, and six weeks can be a long time in melanoma land. So, thinking ahead and building those processes is going to be important moving into the future Dr. Ryan Augustin: Definitely appreciate those practical considerations. Jason, thank you.  Moving on to our final topic, I was hoping to discuss the use of immune cell engagers in melanoma. So, similar to CAR T therapy, bispecific T-cell engagers, or BiTEs, as they're commonly known, are standard of care in refractory myeloma and lymphoma. But these antibodies engaging CD-3 on T cells and a tumor specific antigen on cancer cells are relatively new in the solid tumor space. Tarlatamab, which is a DLL-3 and CD-3 bispecific antibody, was recently approved in refractory small cell lung cancer, and, of course, tebentafusp, an HLA-directed CD-3 T cell engager was approved in uveal melanoma in 2022. Both T and NK cell engaging therapies are now offering hope in cancers where there has historically been little to offer. However, similar to our discussion with TIL therapy, bispecifics can lead to CRS and neurotoxicity, which require considerable logistical support and care coordination.  Jason, I was wondering if you could briefly discuss the current landscape of immune cell engagers in melanoma and how soon we may see these therapies enter the treatment paradigm for cutaneous disease. Dr. Jason Luke: I think it is an exciting, novel treatment strategy that I think we will only see emerge more and more. You alluded to the approval of tebentafusp in uveal melanoma, and those trials were, over the course of a decade, where those of us in solid tumor land learned how to manage cytokine release syndrome or the impact of these C3 bispecifics, in a way that we weren't used to. And what I'll caution people is that CRS, as this term, it sounds very scary because people have heard of patients that, of course, had difficult outcomes and hematological malignancies, but it's a spectrum of side effects. And so, when we think about tebentafusp, which is the approved molecule, really what we see is a lot of rash because GP100, the other tumor antigen target, is in the skin. So, patients get a rash, and then people do get fevers, but it's pretty rare to get more than that. So really what you have to have is the capacity to monitor patients for 12 hours, but it's really not more scary than that. So it really just requires treating a few people to kind of get used to these kinds of symptoms, because they're not the full-on ICU level CRS that we see with, say, CAR T-cells.  But where is the field going? Well, there's a second CD3 bispecific called brenetafusp that targets the molecule PRAME, that's in a phase 3 clinical trial now for frontline cutaneous melanoma. And tebentafusp is also being evaluated in cutaneous melanoma for refractory disease. So, it's very possible that these could be very commonly used for cutaneous melanoma, moving into, say, a two-to-four-year time horizon. And so therefore, getting used to what are these side effects, how do you manage them in an ambulatory practice for solid tumor, etc., is going to be something everyone's going to have to learn how to deal with, but I don't think it should be something that people should be afraid of.  One thing that we've seen with these molecules so far is that their kinetics of treatment effect do look slightly different than what we see with more classic oncology therapies. These drugs have a long-term benefit but doesn't always manifest as disease regression. So, we commonly see patients will have stable disease, meaning their tumor stops growing, but we don't see that it shrank a lot, but that can turn into a very meaningful long-term benefit. So that's something that we're also, as a community, going to have to get used to. It may not be the case we see tumors shrink dramatically upfront, but rather we can actually follow people with good quality- of-life over a longer period of time.  Where is the field going? You mentioned tarlatamab in small cell lung cancer, and I think we're only going to see more of these as appropriate tumor antigens are identified in different tumors. And then the other piece is these CD3 engagers generally rely upon some kind of engagement with a T cell, whether CD3 engagers, and so they can be TCR or T-cell receptor-based therapies, although they can be also SCFV-based. But that then requires new biomarkers, because TCR therapy requires HLA restriction. So, understanding that now we're going to need to profile patients based on their germline in addition to the genomics of the tumor. And those two things are separate. But I would argue at this point, basically everybody with cutaneous melanoma should be being profiled for HLA-A(*)0201, which is the major T-cell receptor HLA haplotype that we would be looking for, because whether or not you can get access immediately to tebentafusp, but therefore clinical trials will become more and more important.  Finally, in that T-cell receptor vein, there are also T cell receptor-transduced T cells, which are also becoming of relevance in the oncology community and people listening will be aware in synovial sarcoma of the first approval for a TCR-transduced T cell with afamitresgene autoleucel. And in melanoma, we similarly have TCR-transduced T cells that are coming forward in clinical trials into phase 3, the IMA203 PRAME-directed molecule particularly. And leveraging our prior conversation about TILs, we're going to have more and more cellular based therapies coming forward, which is going to make it important to understand what are the biomarkers that go with those, what are the side effect profiles of these, and how do you build your practice in a way that you can optimally get your patients access to all of these different treatments, because it will become more logistically complicated, kind of as more of these therapies come online over the next, like we said, two to four years kind of time horizon. So, it's very exciting, but there is more to do, both logistically and scientifically. Dr. Ryan Augustin: That's excellent. Thanks, Jason, and thank you so much for sharing your great insight with us today on the ASCO Daily News Podcast. Dr. Jason Luke: Thanks so much for the opportunity. Dr. Ryan Augustin: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode, and you can follow Dr. Luke on X, formerly known as Twitter, @jasonlukemd. And you can find me, @RyanAugustinMD. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: @ryanaugustinmd Dr. Jason Luke @jasonlukemd   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Ryan Augustin: No relationships to disclose Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

The first episode will launch a week from now, Monday, November 4th!  In this pre-season episode I want to tell you a little about how to listen to the podcast and how I envision it to be useful. I'll also talk about who I imagine my audience to be, how I'm using the term “classical,” and why I decided to create the show in the first place.  Links:  Episode transcript: https://classicallyuntrainedpodcast.com/2024/10/28/pilot-how-to-use-the-classically-untrained-podcast/ Season schedule: https://classicallyuntrainedpodcast.com/episode-schedule/ Newsletter: https://classicallyuntrainedpodcast.com/newsletter/ Anonymous answers: https://classicallyuntrainedpodcast.com/anonymous-answers/ Community: https://classicallyuntrainedpodcast.com/community/ Sponsor an artist: https://classicallyuntrainedpodcast.com/sponsor-an-artist/ Website: https://classicallyuntrainedpodcast.com/  Instagram: https://www.instagram.com/ema_katrovas_podcast/

Back to Basics: What to Wear at the Dog Show Veronica Wolfe from Best in Show Clothes joins host Laura Reeves to talk just basic what to wear at the dog show, how to be comfortable, how to live your own truth and still be respectful of the environment that we're in. They cover outfits for the fall weather's coming up and a little bit about good colors with your dogs and stand out versus blend in. “So, when my junior was becoming a teen and bucking the suits, I reminded her that this is a sport like any sport and every sport has a uniform,” Wolfe said. “I mean, if you're going to be in the soccer team, you get assigned a uniform and there's no, ‘oh, well, it's not my color,' too bad, you know, that's what you have to wear. But fortunately, in the dog show world, we have a little more flexibility. [caption id="attachment_13179" align="alignright" width="526"] Tall, flat heeled boots, a skirt, vest and turtleneck make a classy fall outfit.[/caption] “Looking professional is the key. Well, what does that mean in the dog show world? Classically, men will be in two -piece suits, or slacks, and maybe a tweed blazer for fall, right? And the women will either be in professional dresses or a two -piece suit, whether it's a pantsuit suit or skirt suit. That's the general uniform that you see out there. “Alternatives to blazers because we were kind of talking about dressing to your truth right so not everybody wants to be in a blazer. “I personally hate blazers. I've got broad shoulders, busty, and I'm tall. They're not my favorites. “So a lot of things I like to find and more than ever you can find stretchy fabric like this one actually has some stretch to it just look for spandex in the list of fabrics. Cardigans look great. A navy blue cardigan with a floral skirt … you can find some really nice cardigans and you can find them in every color of the rainbow “The other thing you need to consider is your movement when you choose what you're going to wear and you also need to consider what looks good with your color and your dog's color.”

The Fretless guest on The Stew. Karrnnel Sawitsky and Trent Freeman - one-half of The Fretless join us. Saturday in the first hour.   Their album - Glass Wing is brilliant. With 3 songs cowritten and sung by Madeleine Roger. Classically trained, raised on rock, jazz, blues, folk and heritage roots, they take all those influences and combine them into a sound unlike any other group. They take 100 year old shanty's and reshape the song without losing the original melody so it can last another 100 years. In Glass Wing, they write all their own tunes. Three co-written with Madeleine Roger. There is such joy in hearing violins, violas and cellos driving the beat where normally the drums and bass would be. Impressive my friends.  Very impressive. Have a listen to Pipe Dreams!   The Queen Nancy - named after a car and a make-believe BC Ferry. Icarus - a Madeleine beauty Or the lead track Lost Lake.   This marks a new chapter The Fretless. With Lights, sound and stage design created especially for this album, these songs and this tour. The Fretless Tour  Oct 3  Fanny Bay Oct 4 Comox Oct 5 Victoria Oct 6 Van October 10 Calgary October 11 Edmonton  

Hosted by David and Nycci Nellis.   On today's show:   ·        Taste of Bethesda is back Saturday, Oct. 5. Stephanie Coppula, The director of marketing and communications for the Bethesda Urban Partnership is in with the details, and she's brought along Julio Mejia from the Cubanos Restaurant to mix up some tasty cocktails as well as return guest Molly Gibson from Rooted3 with the veggie-based drinks we love;                                                                                                                         ·        Pepe Moncayo is the executive chef at Cranes and the new Arrels. That word  "roots" in Catalan and is Chef Pepe's latest restaurant concept, set to open at the Arlo Washington DC hotel this fall. Chef is from Barcelona, one of our favorite cities, and his menu will showcase a modern take on classic Spanish cuisine;                                                                                                                                                                                                                                                            ·        Cork's new executive chef Cicile Mendy – you may know her from her stint at Et Viola! -- is here with owner Diane Gross. Classically trained, she's busy serving the French cuisine you know and love that pairs so well with Cork's selection of sustainable wines from small producers;   ·        This is a food lover's alert – Food History Week is coming to the Smithsonian's National Museum of American History. The line-up of foodie entertainment and education activities is, in a word, awesome. Paula Johnson is the curator of food history at the museum, and she joins us with all the info.             Learn more about your ad choices. Visit podcastchoices.com/adchoices

Classically-liberal South African YouTuber Sihle Ngobese AKA Big Daddy Liberty takes a hot seat on The Burning Platform to give his take on some of the week's political stories and interrogate whether the Government of National Unity (GNU) is the solution to the issues South Africa currently faces. The Burning Platform

Classically trained pianist and rapper Chilly Gonzales performs from his new album Gonzo, ahead of his Royal Albert Hall gig, As Hard Times kicks off Radio 4's season of Dickens dramas - what makes a good adaptation? Writer Graham White and Dickens expert Professor Juliet John discuss how the characters and issues like social inequality help to keep the stories relevant to modern audiences. And what is the enduring appeal of horror films? Director Daniel Kokotajlo's folk-horror Starve Acre was inspired by his admiration for 70s classics like The Wicker Man and Anna Bogutskaya's book Feeding the Monster explores how horror films have evolved, and now often explore people's internal trauma and anxieties. Presenter: Samira Ahmed Producer: Paula McGrath

The first season of Classically (Un) Trained will run from October to December 2024. For more information visit: https://classicallyuntrainedpodcast.com/

Kathy Fincher creates meaningful artwork that moves the soul. She is renowned for her Norman Rockwell style paintings of children. Classically trained, her attention to details and lighting have earned her many international awards.  Fincher's painting, The Dream Keepers, was presented to the president in the Oval Office and later inducted into the permanent collection of the G.B. Bush Presidential Library.  For the city of Duluth, Georgia, Fincher designed The Dream Keepers 911 Memorial, featuring seven children using their handprints to restore the American flag, encased in glass and aged brick.  Her greatest work to date is the monumental bronze of Dr. Martin Luther King, Jr. where she captures his premonition of death with his eyes longing for heaven. 

July 12, 2024 Ep 512 - To the Edge of Death and Back Guest: Paul Dragan   By Stuart McNish Ten years ago on June 10, 2014, Paul Dragan sat down to enjoy a cup of coffee across the street from his business, Reckless Bikes. He took a sip and as he looked up, a heavyset man wearing a bicycle helmet came around the corner, pulled out a gun and shot Paul in the chest. He landed on the ground, blood pouring out of his chest.   “Were it not for a series of remarkable events, I'd be dead,” says Dragan. “A doctor was standing feet away at the time I was shot. An ambulance miracle – Vancouver Hospital was minutes away and 14 minutes later, I was in the emergency room with my life in the hands of a surgeon who was not going to let me die.”   Six days later Dragan woke up in a hospital bed, his wife and son next to him. For six days, they've been racked with the fear that Paul would die. “Classically,” says Dragan, “my first words were, ‘Where am I and what happened?' I had no idea. I don't even recall being shot or anything else from that morning.”   We invited Paul Dragan to join us for a Conversation That Matters about his incredible journey to the darkness of death and back.   You can see the interview here https://www.conversationsthatmatter.ca/   Learn More about our guests career at careersthatmatter.ca

Amber Nolan, third grade teacher at Hillsdale Academy, joins host Scot Bertram to discuss prepping for her first year as a classical school teacher, learning lessons during that first year, and working with parents.See omnystudio.com/listener for privacy information.

It's time to head back to school—but this year, for some Jewish students in North America, school is going to look a little different. Some will be receiving what's known as a "classical" education: a curriculum based on a return to fundamentals, a focus on time-tested great books and a rejection of mandates that emphasize diversity and inclusion. There are plenty of classical schools popping up, including Jewish ones. The Emet Classical Academy in Manhattan is welcoming its first-ever cohort of students this fall, with its founders kickstarting their work earlier than expected due to parents and students feeling unsafe in the public system. Rabbi Mark Gottlieb, the chief education officer of the Tikvah Fund, which operates the school, joins to explain why his team felt compelled to create a new space for Jewish students of all backgrounds. And before that, Rabbi Eric Grossman, head of school at the Akiva School in Montreal, sits down with Avi and Phoebe to talk more broadly about this trend toward classical education in Jewish circles and beyond. To wit: if most of Jewish education is based on the Torah and Mishnah, how much more classical can you get? Credits Hosts: Avi Finegold and Phoebe Maltz Bovy (@BovyMaltz) Production team: Michael Fraiman (producer), Zachary Kauffman (editor) Music: Socalled Support The CJN Subscribe to the Bonjour Chai Substack Subscribe to The CJN newsletter Donate to The CJN (+ get a charitable tax receipt) Subscribe to Bonjour Chai (Not sure how? Click here)

Autoimmune cerebellar ataxia and other autoimmune movement disorders encompass a broad spectrum of different clinical syndromes, antibodies, and immunopathophysiologic mechanisms. Given the overlap between phenotypes and antibodies, panel testing in serum and CSF is recommended. In this episode, Gordon Smith, MD, FAAN, speaks with Bettina Balint, MD, author of the article “Autoimmune Movement Disorders,” in the Continuum August 2024 Autoimmune Neurology issue. Dr. Smith is a Continuum® Audio interviewer and professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Balint is an assistant professor for clinical research on complex movement disorders and Parkinson's diseases, a consultant neurologist, the head of the Department of Movement Disorders, and co-lead for the Centre for Movement Disorders and Functional Neurosurgery in the Department of Neurology at the University Hospital Zurich in Zurich, Switzerland. Additional Resources Read the article: Autoimmune Movement Disorders Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME.   Dr Smith: This is Dr Gordon Smith. Today, I'm interviewing Dr Bettina Balint about her article on ataxia and other autoimmune movement disorders, which appears in the August 2024 Continuum issue on autoimmune neurology, which is a highly anticipated and exciting issue. Dr Balint, welcome to the podcast, and, perhaps, you can just introduce yourself to our audience and tell us a little bit about your practice and how you became interested in this topic.   Dr Balint: Thank you, Gordon, for having me. I am an assistant professor for clinical research in complex movement disorders and Parkinson's disease at the University of Zurich and the Head of the Movement Disorders Department at the University Hospital in Zurich. So while I'm originally German (from Heidelberg), I have now been to Switzerland since end of 2021.   Dr Smith: So, you know, how many movement disorder chiefs have a focus on autoimmune movement disorders? I found that really interesting. Most of the movement disorder folks I interact with, their primary interest is in neurodegeneration.   Dr Balint: Very good question. Even so, I never asked myself that question, really, but I think I'm the only one with this designated focus as such. Many people come from the neurology angle - most of them. Even so, movement-disorder people really welcome this field and are interested, but I think somebody who has dedicated their interest and time to it? I think I can't actually think of many other people.   Dr Smith: Yeah, I think it's really cool, and, of course, autoimmune neurology is the flavor of the day these days, right? I mean, I remember when I was at the University of Utah, we were recruiting Stacy Clardy (who I think many of our listeners will know). I remember thinking, you know, she's never going to be busy. How many of these autoimmune problems are there, really? And she was, like, deluged when she came. These are really common problems. I guess that was one question I had for you. You know, we think of these as rare disorders, and when we look at the article, you have these tables of these antibodies, and a lot of them are pretty uncommon – but, cumulatively, how common are autoimmune movement disorders?   Dr Balint: It's a very difficult question, because we don't have good epidemiological data. And if you look at series, I mean, most papers addressing this issue come actually from the ataxia field. And then, depending on where you look at, you might find varying numbers, and they might be also influenced by the fact that they come from ataxia centers with own certain biases. Even so, it's very close to my heart, but, I also still think it's overall very rare. So, in my practice, I see all sorts of movement disorders, and overall, they're still quite rare, but the point is that they are treatable and have important management implications, so you want to be sure not to miss any of them.   Dr Smith: Well, maybe we can go to that next. Part of the challenge here, of course, is there's just so many of these different syndromes and antibodies. Are there pearls that you can provide our listeners that would help them guide when they should be thinking about these disorders when they confront a patient with a particular phenotype? Like ataxia, for instance - you know, there are certain aspects of the clinical scenario that should trigger, “Wow, this might be an autoimmune problem”.   Dr Balint: So, in general, I would say there are certain scenarios where you would want to think of an autoimmune etiology in your differential. One is a very characteristic phenotype. So, speaking broadly in terms of movement disorders, stiff-person spectrum disorders have a very characteristic phenotype which you need to recognize, and then you will be able to see it when a patient enters. Important phenotypes to know which are very characteristic are faciobrachial dystonic seizures, for example, with anti-GA1 antibodies, or pseudofinalistic movements in non-REM sleep is IgLON5 antibodies, leg myoclonus is CASPR2 antibodies. I don't want to necessarily enumerate all the scenarios. The point here is there are some characteristic phenotypes where you would think of autoimmune neurology. Another scenario where you would think of autoimmune, for example, the context of late-onset paroxysmal movement disorders. So, classically, when we think of paroxysmal dyskinesia, we think of a group of genetic disorders, but if somebody develops a paroxysmal movement disorder later in life in adulthood, then you would think of autoimmune neurology, and this applies also in the context of episodic ataxias. Another red flag might be a propensity to autoimmunity. For example, somebody with type one diabetes and vitiligo coming in for cerebellar ataxia, of course, you would think of anti-GAD ataxia. And, similarly, if somebody has recently been diagnosed with a cancer and develops a rapidly disabling syndrome, of course, then you would think of a paraneoplastic autoimmune disorder. And with autoimmune syndrome, there are some symptoms which are also like tell-tale signs. So, for example, somebody with a stiff-person spectrum disorder, an ataxia with long-lasting diarrhea over months, losing weight - investigations haven't found anything, then you would think of DPPX antibodies or celiac disease. Or, if you have, like, a neuropathic pain which is otherwise not explained, then you might think of CASPR2 antibodies in somebody with a cerebellar ataxia. So, there are some features of some antibodies. (Again, I will not now list all of them which might point you to a diagnosis.) Then, of course, another scenario which is important, I think, is if you have a hemisyndrome without a structural lesion on imaging. Classically, neurologists are trained to think of a hemisyndrome - we look for a lesion on the contralateral side. But if you have, like, for example, a hemichorea without a lesion or a hemiataxia without a lesion, one should also think of an autoimmune disorder with antibodies. And then, more generally, of course, if you have changes on brain MRI or information on CSF, of course, if the clinical cause is more rapidly progressive - and last, but not least, if somebody does not really fit into our categories of the degenerative symptoms or metabolic syndromes or functionality disorders, then, of course, one should just take a step back and think, could it be something autoimmune? Having said that, if I may, I just want to say that, I mentioned that rapid disease course, and on the other hand, it's important to stress that a slowly progressive disease cause does not exclude an autoimmune etiology.   Dr Smith: So, that was a great summary. Thank you. I don't know if you're familiar with the term “Aunt Minnie” (something I learned in medical school and radiology). There are certain findings that are “Aunt Minnie”, you know what “Aunt Minnie” looks like, and if you see these particular findings, you should really think about a specific disease - and I think you gave a lot of pearls in that answer, so I appreciate that. This may seem like a bit of a random question, but it's interesting that there are some of these phenotypes that do replicate genetic phenotypes, and you used episodic ataxia, which, in a younger individual, we think of a spectrum of various genetic disorders. Is that random, or are there instances where the underlying mutation in a genetic disorder actually serves as a target for autoimmunity in a later-onset autoimmune problem? Not that the mutation causes autoimmunity, but are there shared targets - in one disease it's the mutation, and another, there's an antibody that binds to the protein, for instance?   Dr Balint: That's an excellent topic, and even though it's not addressed in the Continuum article, I actually covered this in an article in Brain from 2018, where we also discuss parallels (immunogenetic parallels) with targets seen in genetic disease or in autoimmune disease, and there are actually some examples for cerebellar ataxia, and some of the targets are, indeed, the same for the antibodies and mutation. And some targets are a little bit more difficult, because for those, the antibodies would probably not be pathogenic, but it's more like an autoimmune overall target but it's T-cell mediated. But, for example, water-gated, um, calcium channels - we have antibodies and we have mutations. Or, another example would be glycine receptor antibodies give you acquired hyperekplexia, whereas the mutations give you hereditary hyperekplexia. So, there is, indeed, a bit of an overlap between autoimmune and genetic disorders, but often, also, like, the age at onset (because that might be the next question, the age at onset), and maybe family history and associated features, should help to distinguish the two. I think more from the pathophysiological point interesting, rather than clinically too confusing.   Dr Smith: Wow, that's really cool. So, another question I have is regarding antibody panels, right? And so, I think, oftentimes (at least around here), folks confronting an unusual phenotype will send the Mayo panel - they'll send autoimmune encephalitis or a paraneoplastic panel – and, you know, I think one of the challenges I have thinking about the spectrum of phenotypes that you described, I mean, if you recognize “Aunt Minnie”, then you know where to go, but it seems to me that there's a lot of these that maybe folks don't recognize “Aunt Minnie”. What is the diagnostic utility and pearls and pitfalls of ordering these panels when you're not really certain? In other words, is there a risk of a false positive if the pretest probability is low? So, I guess that's a long question, but do you have guidance about when we should and maybe when we should not be ordering these panels? So, you know, undifferentiated ataxia that's chronically progressive - should we be sending a panel or not? Patients who are later-onset acute, maybe so. So, what's the guidance on when to order the panel?   Dr Balint: It's a tricky topic also for many people in our practice, because, of course, as you said, we don't want to miss something, but, indeed, with any test which you order with a low pretest probability and which is not quite appropriate, you might have false positives, and that might cause much additional trouble in security, or maybe unnecessary and invasive immunotherapy with adverse effects – so, it's really important to think well about antibody testing. And, generally speaking, like always in medicine, we shouldn't order random tests, and antibody panels and neuronal antibodies are not designed as a screening test, so you need to have a phenotype and a reasonable suspicion - and clinical acumen is really key, and that's why also the article is so much focused on the phenotype. It's clearly not that any movement disorder patient who enters the outpatient clinic should get a blood test for antibodies that will likely cause harm, and it has been shown that these antibodies can be falsely positive, both in other diseases but also in healthy controls, and much depends also on which tests you use (but, let's not go into too much detail over here) - so, generally speaking, I would say if you have a suspicion of an autoimmune disease clinically (I mentioned some scenarios where you would think of an autoimmune disorder). And then, ataxias are, of course, a bit tricky, because often, we don't have too many other handles there, and there's still also a significant number of acquired late-onset ataxia where we don't know what the cause is. I think in the ataxia scenario, if I don't have a good answer or explanation, I would order antibody tests a bit more freely - I mean, if you do it properly, you do the serum and the CSF, and that also increases your sensitivity but also the specificities, so I wouldn't then just do the serum, but then go for serum and CSF. In other movement disorders, it depends also a little bit on the phenotype. So, somebody with a phenotype fitting well with Parkinson's disease, I wouldn't do any testing. Somebody with clear PSP phenotype without any red flags or not-fitting features, it is very unlikely to have an antibody finding, and this has been shown also in cohorts. But, if you have something which is not fitting in the phenotypes - for example, you have somebody where you think it might be a PSP phenotype with predominantly axial Parkinsonism falls, but you notice that the oculomotor disturbance is not a vertical gaze palsy, but a horizontal gaze palsy – so, it's not really fitting phenotype as you know it. That's a scenario where would probably think of antibody testing. Then, if you do the testing theorem - and CSF, in general, is gold standard - there are some antibodies where theorem is good enough (like, for example, with aquaporin-4 antibodies), but the reason why we do serum and CSF, as I mentioned, is the increased sensitivity and specificity. And nowadays, in the antibody world, we have something similar to the genetics - we have the variant of unknown significance and in the neurology world, we coin the term “antibody of unknown significance” to also give a name to the problem that, sometimes, we get a test result and it is difficult to interpret. Another handle over there would be to try to confirm the test result in another test method. So for example, if you have a cell-based assay with an antibody finding, you would like to confirm that on immunohistochemistry - the staining pattern is in keeping with that.   Dr Smith: So, Bettina, that was a really great and comprehensive answer to the question with a lot of pearls packed into it, and I think the idea that, you know, oftentimes, it's helpful to do both serum and CSF testing is important - also looking for staining to further confirm the diagnosis. And, I think one of the things that I was struck by in your response was the example of a PSP patient who instead of vertical gaze palsy had horizontal gaze palsy as a red flag, and I think a lot of our listeners are probably familiar with the idea that maybe hyperkinetic movement disorders might be autoimmune, or certainly rapidly progressive ataxia, but at least I don't think of Parkinsonian syndromes as often. I know there are some that we need to consider. Maybe you can give us some pearls about when we should consider antibody testing in a patient who has a Parkinson syndrome?   Dr Balint: So, I will not cover now the paraneoplastic Parkinsonian syndromes (because they typically develop as rapidly that you would anyway think about it, hopefully), but go more into those conditions which might mimic degenerative disease - and one of the most interesting antibodies in this regard is IgLON5, and you will be aware that it has been discovered in 2014 in patients who shared a characteristic sleep movement disorder (non-REM parasomnia). The spectrum has broadened a lot, and one possible manifestation is that it could come into the differential of Parkinsonian syndromes - so, for example, if you have axial Parkinsonism and a gaze palsy, you are in a PSP phenotype, but the red flag would be maybe if the eye movement disorders are not really fitting with the PSP phenotype. Also, in PSP patients, we don't expect parasomnias at night. If the bed partner is, for example, complaining that the patient is moving in his sleep and doing movements, then this would be a red flag, and in this context, you would think of IgLON5. IgLON5 could also give you Parkinsonism and cerebellar ataxia, and they might have dysautonomia, and, of course, with a sleep movement disorder, you are now in the ballpark of MSA phenotypes; however, if there are additional features (like, for example, fasciculations) which you don't expect in MSA, that would be, again, the red flag. So, typically, even in those differentials, there are some red flags on handles which would point you to the diagnosis - it is not that it completely mimics the phenotype of our default degenerative disease, but, sometimes, you need to hunt a little bit for those handles.   Dr Smith: So, Bettina, that's really interesting. I wanted to ask you about IgLON5, and in particular, the sleep phenotype, but, you know, I wonder whether there's a risk of just confusing this with REM sleep behavior disorder and a chronic Parkinsonian syndrome - what's the time course of this, and any other wisdom in terms of how to differentiate it from, you know, a more common neurodegenerative problem?   Dr Balint: So, the spectrum of sleep disorders in IgLON5 is actually a bit broad. The characteristic thing is the non-REM sleep parasomnia with the finalistic fine movements, but classic REM sleep behavior disorder has also been reported in these patients. And one of the tricky things is IgLON5 is a slowly progressive disease (some patients had symptoms for a decade prior to diagnosis), so it's really an important differential of autoimmune disease - but as mentioned, the features not fitting in, and they are typically also the cardinal features. So, gaze palsies are very frequent, ptosis, bulbar symptoms, vocal cord palsy, sleep movement disorders which might not fit to the original phenotype, and breathing problems (for example) so severe that they require a tracheostoma – so, these are some red flags which would alert you to this diagnosis of anti-IgLON5 disease.   Dr Smith: I'm curious, Bettina, how do you keep up on all of this and keep it all straight? Right, there's a lot of information, and as I was reading your article, you've got these wonderful tables - and in fact, this whole issue for our listeners feels that way. I've read several of these articles now, and I'm just curious what your strategy is to stay up to date and stay organized. You have to be very organized to be an autoimmune neurologist, it seems to me.   Dr Balint: And having a little bit of OCD helps clearly, as always, in neurology. I think it is just that I started to be interested in this area for a while and I have in my head the clinical phenotype to most important associated antibodies, and as the field continues, I just add up on that panel. But, I don't want people to be discouraged - you're right, many antibodies, but I think the point is not to know each and every antibody but to know in which scenario to think of an autoimmune syndrome and then to know where to look it up.   Dr Smith: Well, I think that's a great way of ending our conversation, Bettina. I think your article does a great job of that, and one of the things I love about Continuum is these articles serve as point-of-care tools. I think our conversation will also serve as a useful framework, because I think you've talked a lot about how to organize your thinking, and, you know, pearls for when we should be thinking about these disorders which are uncommon, but you certainly don't want to miss one because the therapy can be very effective. So, Bettina, thank you so much for joining me. This has been a really great conversation.   Dr Balint: Thank you so much, Gordon. Thank you very much for your good questions.   Dr Smith: So, again, today, I've had the great pleasure of interviewing Dr Bettina Balint, whose article on ataxia and other autoimmune movement disorders appears in the most recent issue of Continuum, which is on autoimmune neurology. Be sure to check out Continuum Audio episodes from this and other issues. And thanks to our listeners for joining us today.   Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at Continpub.com/AudioCME. Thank you for listening to Continuum Audio.

What's the Community Day Classic Pokémon? Well, there are no Beldum questions! Bring sun and sand to your home by watching the Pokémon World Championships! …and more on this episode of GOCast! Chapters: 00:00:00 - Intro 00:10:20 - News 00:20:29 - Gear Up 00:29:30 - PokéLore 00:35:34 - PokéPoll 00:46:26 - Emails/Voicemails News Links: August 2024 Community Day Classic: Beldum - https://pokemongolive.com/en/post/communityday-classic-beldum/ Visit our website - ⁠⁠www.gocastpodcast.com⁠ Support us - ⁠⁠www.patreon.com/gocastpodcast⁠ ⁠⁠⁠Email us - ⁠⁠mail@gocastpodcast.com⁠ ⁠⁠⁠Email PvP Corner - pvpcorner@gocastpodcast.com Follow us on X - ⁠⁠@gocastpodcast⁠⁠ Leave us a voicemail - (262) 586-7717‬ P.O. Box address: GOCAST PODCAST PO Box 367 301 E Congress Pkwy Crystal Lake, IL 60039

In what I hope is the last update before I launch the first season of the new podcast, in this episode I will: 1) Tell you about audience survey results (including reading out some responses about performing artists' frustrations and responding to a repeating theme which surprised me) 2) Describe the podcast to come (including some titles of episodes I'm writing) 3) Tie up some loose ends from the last podcast! Currently the best way to stay up-to-date is the newsletter, which you can sing up for HERE. New Website (under construction): classicallyuntrainedpodcast.com Here is a full written presentation of the new podcast: Classically (Un)Trained - Performing Artists (Re)Inventing Themselves in Times of Hardship and Technological Change  Classically (Un)Trained is a companion for classically-trained performers who are on a journey to (re)invent themselves for the 21st century and (re)discover meaning in what they've trained so hard to master.   … Performing arts degrees are likened to pyramid schemes, auditions are called cattle calls, and artists who make a living from performing are the 1%.  If you're a classically-trained actor, singer, instrumentalist or dancer, you've heard these quips before and you're well aware - thank you very much - that you've trained hard to fit into a very elite but, as it turns out, very overcrowded market - and one that is shrinking under your feet.  Most advice for young performers focuses on how to break into the industry, make enough money from gigging, or find the right parallel career. Those things are important, but something's missing. What about the need to find meaning in what you do, beyond just chasing after your next stage "fix"? What about the fundamental need to be part of a community of people you respect and admire, not just ones you need to outcompete? What about the importance of doing something you know is relevant, meaningful and even, dare we say, essential?  In every episode of the first season of Classically (Un)Trained, we'll explore artistic solutions to the economic, social, and technological problems facing the 21st century classically-trained performing artist and explore how performers can find meaning in their work not just despite of, but also thanks to, the unique challenges they face today.  About the host: Ema Katrovas is a classically-trained singer. She spent her formative years singing in regional Czech theatres. After the pandemic, she pivoted to contemporary classical music and cultural journalism, attending the Aix-en-Provence festival's cultural journalism workshop and completing a two year Artist Diploma residency at the High Conservatory in Lyon, where she created and performed in the one-woman vocal-theatre show Diva Lazarus*. She is currently working on a doctorate at the University of Strasbourg/HEAR with a thesis called* A Poor Opera: In Search of Vocal Theatre. www.emakatrovas.com

"Ferera Swan is a recording artist, songwriter, composer, pianist, violinist, and GRAMMY voting member of The Recording Academy. Today, the Austin, Texas-based cinematic-pop artist is boldly emerging from a transformative time of reclamation. Classically trained with the Suzuki Method, Ferera began piano lessons at age 3, violin at age 6, and began writing pieces for piano by age 10. By age 16, she composed her first cinematic score titled “Serenity”, which was premiered by four high school orchestras and piano after winning a district festival composition contest her senior year. Working out of her home studio in Austin, Texas to date, Ferera has released two albums under previous artist names and has written, co-produced, co-engineered, and arranged music for other artists in a wide variety of genres ranging from pop R&B, country, rock, and folk, as well as having worked as a vocalist, pianist and/or violinist session musician. Her vocals and voice-over work has been featured in various commercial jingles including a national advertisement for Old Navy, while also performing her original music live on radio and television in the Austin, Texas region. Her instrumental piece, “Lighthouse” was featured in the film documentary ‘Swim For The Reef' that premiered at the Cannes Film Festival in France. Sharing her personal story through music as an artist and adoptee, Ferera is passionate about raising awareness around adoption in support of family preservation and evolving society's mainstream adoption narrative. Her music is a vulnerable, unfiltered, and honest expression of the ongoing healing journey relevant to many, reaching the hearts of all listeners. Currently, Ferera is actively working on upcoming projects and over the past year, has helped launch Women In Music's very first Austin Chapter as Vice Co-Chair of Membership. Bridging music and activism for adoptee rights, social change, and collective healing, Ferera has channeled her trauma into a creative and personal rebirth. “Some of our greatest gifts can be found in our deepest pain. Explore what hurts, and find yourself."' https://www.fereraswan.com

Muehlhan Wind Service acquires a controlling interest in Portugal's Endiprev to create a global front runner in wind installation and maintenance services. Energy Capital Partners raises over $4.4 billion for its latest fund focused on power generation, renewables, and decarbonization infrastructure. FiberLine Composites is moving all production from Denmark to India over competition from Chinese manufacturers, while also working on domesticating some production in the U.S. to take advantage of tax credits. Sign up now for Uptime Tech News, our weekly email update on all things wind technology. This episode is sponsored by Weather Guard Lightning Tech. Learn more about Weather Guard's StrikeTape Wind Turbine LPS retrofit. Follow the show on Facebook, YouTube, Twitter, Linkedin and visit Weather Guard on the web. And subscribe to Rosemary Barnes' YouTube channel here. Have a question we can answer on the show? Email us! Pardalote Consulting - https://www.pardaloteconsulting.comWeather Guard Lightning Tech - www.weatherguardwind.comIntelstor - https://www.intelstor.com Allen Hall: I'm Allen Hall, president of Weather Guard Lightning Tech, and I'm here with the founder and CEO of IntelStor, Phil Totaro, and the chief commercial officer of Weather Guard, Joel Saxum, and this is your News Flash. News Flash is brought to you by your friends at IntelStor. If you want market intelligence that generates revenue, then book a demonstration of IntelStor at IntelStor. com. Danish company Muehlhan Wind Service has acquired a controlling interest in Endiprev, a Portugal based company specializing in commissioning and electrical work for the wind industry. This acquisition aims to create a global front runner in wind installation and maintenance services. Endiprev will continue to operate under its existing brand with current executive management team remaining in place. Muehlhan has expanded significantly over the past seven years and has acquired several companies in the last 18 months. And Phil, this seems to be the trend in any sort of repair, maintenance company is to acquire, acquire, acquire. Philip Totaro: At this point, yes, Allen. And it's interesting because we've talked over the past, six to 12 months about Any number of different deals where companies have either kind of merged together an EPC contracting capability with maintenance services or maintenance providers getting together in some cases, maintenance providers acquiring supply chain, smaller, tier three or four supply chain companies as well. So, I mean, this is, it's starting to get serious. We've talked on the show before about, the increased need for maintenance services, quality of maintenance services, et cetera. And this puts Muehlhan and, and Endiprev in in a really great position globally. Joel Saxum: Yeah. So if you aren't familiar with kind of what this business model looks like as it expands is Endiprev being a basically front end commissioning services company, they do a lot of build outs. They do electrical work of these things. Muehlhan has been Classically a more of a maintenance company. So now what you do is you come in on the front end of a project, you help build it or you build it as the EPC is the front runner there. And then when that project switches over to commissioning, which normally you would walk away. Now you just back your other players in there and you've already got built in work for the maintenance and operation side of things. So it's a great tie up and you're going to start to see a lot more of these as well. Allen Hall: Energy Capital Partners, an investor in power transition, electrification, and decarbonization infrastructure assets, has raised over 4. 4 billion for its fifth flagship equity strategy, ECP5, or better called Fund 5. The fund exceeds its initial target by 10 percent and also raised an additional 2. 3 billion in co investment capital. Fund 5 will continue Energy Capital Partners i...

Tami Tack & Kim Worrall graduated from the Hoffman Process in 1996. They took the Process a second time after it was rejuvenated from an 8-day Process to 7 days. Tami and Kim have been stewards of this work ever since. For over 15 years, Tami has been a graduate group leader in the Portland, Oregon area. Tami and Kim speak to the power of learning to trust in and live from the Spiritual Self and softening into its care. Kim first realized that his nature had a spiritual aspect during the Process. Tami and Kim share stories from their post-Process past to illuminate how vital this aspect of our Quadrinity has been to leading joyful lives. You'll hear Tami and Kim speak about how the Process work has been vital to their relationship. The Hoffman Process supports not only our internal transformation. It also transforms our relationships. When two partners have completed the Process and followed it up with the Hoffman Couples Retreat, the work can deepen the quality and power of your relationship. We hope you enjoy this conversation with Tami, Kim, and Hoffman host, Sharon Mor. More about Tami Tack & Kim Worrall: Married since 1987, Tami and Kim enjoy traveling and exploring the inner world of relationships and spirituality.  They host a monthly spiritual Living Circle and have participated in Thom Bond's Compassion Course for two years, an outgrowth of Nonviolent Communication (NVC). Tami and Kim sing together in local choirs and volunteer with CASA (Court Appointed Special Advocates) to work with children in foster care. They live in Tami's childhood country home which they have named Harmony Hill. Enjoying an active life, they hike, bike, and kayak. They are deeply grateful for all that Life has brought them and look forward to the next adventure. More about Tami Tack: Tami first experienced the Hoffman Process in 1996, then again in 2015 after the Process was rejuvenated.  Passionate about Hoffman Graduate Groups, she led the Portland group from 2009 to 2023, mentoring other leaders beginning new groups. She is a retired school counselor and therapist and has always loved working with people of all ages. Another passion of hers is music, expressed both through piano and voice.  Classically trained in piano, she discovered in her 40s that she could compose music and recorded three CDs of her original piano solos. Singing with many choirs, she directs the Lower Columbia chapter of Threshold Choir whose mission is to sing at the bedside of the dying. The proud mother of two delightful adult children and grandmother to four, she prioritizes family and heart connections. More about Kim Worrall: Kim discovered the Hoffman Process in 1996. In 2014, he repeated the HQP, remembering that he is not his patterns—imagine that! A major takeaway was that he has a Spiritual Self. He is curious about how things work, from human thinking and behavior to galaxies and microbes.  He is a retired teacher and counselor, a former pilot and mountain climber, and a father and grandfather. Formerly singing in the Portland Opera chorus, he now sings with a local men's ensemble. Having been interested in magic since he was a kid, Kim has produced magic shows and always carries a bit of magic with him. He loves to travel for its broadening view of our world and people. He is learning the value and strength of vulnerability. As mentioned in this episode: Engulfment Bob Hoffman Hoffman Couples Retreat Hoffman tool: Embodied Recycling Graduate Groups Virtual (Zoom) Grad Meetings are held in four time zones - Pacific, Mountain, Central, and Eastern. Hoffman Process Rejuvenation Neural Pathways Threshold Choir Religious Science Ed McClune: Listen to Ed on the Hoffman Podcast Prayer Wheel

Head to SESAME to save 10% off the most amazing telehealth program ever with my code WITHAY for same day appts (almost always) for everything from Pediatrics, mental health, dermatology, weight loss and illness!! Especially and even if you have health insurance, Medicaid or Medicare!...Meredyth Approved!   Weaving together soaring, angelic vocals and the celestial sound of crystal singing bowls, Ashana is one of the premiere healing music artists of our time. In fact, Ashana's original sound pioneered an entirely new genre of healing music with crystal singing bowls. This exquisitely crafted, luminous sonic tapestry soothes and opens the heart, enfolding the listener in a transcendent experience of the Divine and a direct experience of the Soul. This stunningly beautiful alchemy has been hailed by listeners all over the world as “breathtaking” and “a Gift from Heaven.” Evolving from deep self-exploration, her style is truly eclectic. From her haunting rendition of the Lord's Prayer in the original Aramaic, to a Sufi chant, Latin verse, Gaelic song and Sanskrit mantra and improvised ambient sound, Ashana blends Western and ethnic instruments with the unique drone of the crystal singing bowls to create the ultimate transcendent music for healing, relaxation and meditation. With producer, Thomas Barquee (Snatam Kaur, Seal), Ashana has received wide-spread, international acclaim for her CD recordings All Is Forgiven, Jewels of Silence, Beloved, The Infinite Heart and The Illuminated Path. Her CD, River of Light was selected for the first round of Grammy Nominated albums in the 2014 World Music category. At work in the studio for the last few years, Ashana and Thomas are preparing to release several groundbreaking projects in the near future. An international artist and student of yoga and mantra for most of her life, Ashana has led two worldwide online group yoga meditation experiences, touching the lives of over 20,000 people in more than 50 countries across the globe. Ashana is passionate about nurturing the creative process to bring through just the right words, sound, melody, feeling and expression. Her musical calling came at an early age as a young girl growing up in the Bronx, in New York City. She began singing in churches and as time went on, synagogues, temples, sweat lodges and gurdwaras. Classically trained, she spent many years exploring a wide variety of musical genres including jazz, pop, gospel, musical theater and children's music. From ancient to contemporary she immersed herself, graduating with a degree in vocal studies from the prestigious Mannes College of Music in New York City. Contact Facebook 35K | Youtube 19.9K | Spotify 193K SHOP MUSIC CRYSTAL BOWLS ONLINE COURSES Here's the link to the Free Gift: https://soundofashana.lpages.co/podcast-glhgift Get full show notes, resources, and links on my website! Are you ready to go deeper? I am giving you the keys to the castle. If you enjoyed this podcast and want to hear more, make sure to subscribe so you'll never miss an episode! You can connect with me on Facebook, Instagram, TikTok or Youtube.  

Pack your bags because we are headed to St. Louis for the Classical Association of the Midwest and South's annual conference! That's right, your hosts are not just nerds who really enjoy Classically-inspired media; they're also serious scholars! Our host Christie talks to various participants (some of which are old friends of the podcast) to learn what they love about CAMWS. It's not all serious academic talk though, because at the end of the day, we're ALL big nerds that love to discuss film and Antiquity! Plus, you'll get to learn a little more lore about your hosts! Special thanks to everyone who sat down for an interview, including Christina Hotalen, Michael Hall, Sami Cronin, Andrea Stehle, Jeremy Swist, Amy Norgard, and Abigail Bradford! We have done our best to link their names with sites where you can learn more about them and their work. Be sure to let them know we sent you their way!If you want to learn more about CAMWS, check out the website here: https://camws.org/And if you would like to attend an online conference all about the ancient world in media, be sure to check out AIMS (Antiquity in Media Studies)! Maybe we'll see you there;) https://antiquityinmediastudies.wordpress.com/This special episode also required a little more ambience, so thanks to music from #Uppbeat (free for Creators!):https://uppbeat.io/t/light-patterns/grassland for helping to set the tone! Hosted on Acast. See acast.com/privacy for more information.

Pack your bags because we are headed to St. Louis for the Classical Association of the Midwest and South's annual conference! That's right, your hosts are not just nerds who really enjoy Classically-inspired media; they're also serious scholars! Our host Christie talks to various participants (some of which are old friends of the podcast) to learn what they love about CAMWS. It's not all serious academic talk though, because at the end of the day, we're ALL big nerds that love to discuss film and Antiquity! Plus, you'll get to learn a little more lore about your hosts!  Special thanks to everyone who sat down for an interview, including Christina Hotalen, Michael Hall, Sami Cronin, Andrea Stehle, Jeremy Swist, Amy Norgard, and Abigail Bradford! We have done our best to link their names with sites where you can learn more about them and their work. Be sure to let them know we sent you their way! If you want to learn more about CAMWS, check out the website here: https://camws.org/ And if you would like to attend an online conference all about the ancient world in media, be sure to check out AIMS (Antiquity in Media Studies)! Maybe we'll see you there;) https://antiquityinmediastudies.wordpress.com/ This special episode also required a little more ambience, so thanks to music from #Uppbeat (free for Creators!):https://uppbeat.io/t/light-patterns/grassland for helping to set the tone!

Jason Hawk Harris is a singer and songwriter from Texas whose latest record Thin Places is an examination of grief in a way that speaks so directly to my recent experience. Classically trained and full of creative energy. He is a sweet and thoughtful person who makes incredible records. I am so grateful to bring y'all my conversation with Jason Hawk Harris. Spotify: Apple Podcasts: The Marinade Website:  Follow all things Jason Hawk Harris: https://jasonhawkharris.com/ Support The Marinade on Patreon: https://www.patreon.com/marinadepodcast  

Mario's background Discovering your burning why. As a former business owner, I understand the challenges that many business owners face. My entrepreneurial experience (I'd love to share this story with you)  coupled with extensive and ongoing business training and time spent working with small business owners allows me to now coach other small business owners to great success. I'm blessed to be able to walk alongside small business owners as their coach and influence their future in a positive way! Let's chat and see if Business Coaching is right for you. Just click the button below to schedule a complimentary coaching session. I look forward to learning more about you! Business Coaching Mario@CrystelClearbusiness.com www.CrystelClearBusiness.com Podcast Sponsored by Brackens Painting ServingJefferson, Berkeley, Loudoun, Clarke, Frederick and Morgan county, also Winchester to Martinsburg and Leesburg Your Painting Specialists Since opening our doors for business back in 2011, Brackens Painting LLC has been associated with a high level of quality and professionalism throughout Northern Virginia and the Eastern panhandle of West Virginia. Classically trained by 4 generations of painters, Brackens Painting can still call on many years of experience.  We want to be the first company you think of when you need painting done.

Welcome to another episode of The Women of Austin Podcast! In this installment, Host Mindy Hofman engages in a heartfelt conversation with the remarkable Heather Emerson. While Heather is no stranger to the podcast, having graced our airwaves twice before, this episode takes a more intimate turn as she takes center stage for a solo exploration of her journey. In this enlightening episode, Mindy and Heather delve into the pivotal moments that have shaped Heather's life, starting with her transformative "Eat, Pray, Love" adventure in Tel Aviv. Heather shares her post-college odyssey to New York City, driven by a thirst for personal growth and a desire to break free from the shackles of fear and attachment. Amidst the hustle and bustle of the city that never sleeps, Heather's chance encounters and backpacking escapades paved the way for profound self-discovery. As she recounts her time in Israel, Heather reveals how immersing herself in a new culture and language provided the perfect backdrop for shedding old paradigms and embracing a more authentic way of living. From spontaneous adventures to daily yoga rituals, Heather's journey serves as a testament to the transformative power of exploration and self-reflection. Transitioning to her entrepreneurial endeavors, Heather shares her decision to make Austin her home base alongside her husband, where they are both driven by a shared vision for their business ventures. She offers sage advice for listeners seeking change, advocating for a compassionate approach and trusting in the universe's guidance. In addition to her inspiring journey, Heather introduces her latest venture, Offshore Launch, a platform dedicated to helping entrepreneurs streamline their operations and reclaim their time through strategic delegation. If this episode resonated with you, don't forget to show your support by liking and subscribing. Your encouragement fuels our mission to empower and uplift women everywhere. Thank you for joining us on this journey of discovery and growth!

On this episode of the Classical et Cetera podcast, the table sits down to talk about what the world might look like if everyone could benefit from a classical Christian education. What if our society celebrated critical thinking, philosophical analysis, and engaging with matters of the head and the heart? What if everyone started their careers, businesses, and homes equipped with the tools necessary for the Great Conversation that shaped our world for thousands of years? Memoria Press has dedicated itself to building a homeschooling curriculum that works and is classically educating children around the world. We are ready to answer any questions you might have about starting on this journey in your own home or school. Visit us at memoriapress.com to learn more! https://www.memoriapress.com/?utm_source=YouTube&utm_medium=CETC&utm_campaign=122 Check out our classical core curriculum! https://www.memoriapress.com/curriculum/classical-core-curriculum/?utm_source=YouTube&utm_medium=CETC&utm_campaign=122   #classicaleducation #memoriapress #homeschooling

Chef Fred Nesbitt is one of the country's leading cannabis chefs. Based in San Francisco, Fred is in demand creating dining experiences not for the faint of heart. Classically trained as a chef and augmented with a certification in Cannabis Science & Medicine from the College of Medicine at The University of Vermont, Fred creates delicious edibles from his home and discovers new ways to infuse cannabis into his cooking. T-Bone sent him a bottle each of BBQ sauce from Andy's Smoke on Wheels line and Todd's Plowboys collection and talks about using them at a private party in California just last weekend.www.bbqradionetwork.com www.holsteinmfg.com

Podcast guest 894 is John Martin, Classically trained guitarist, UFO Experiencer, videographer and author of the book the universe loves you. During this video we talk about his CE-6 method of contact and we see videos of UFOs that he has taken. The Universe Loves You https://amzn.to/3qQu9bp John's YouTube Channel https://www.youtube.com/@johnmartinufoandetintellig254/featured John's Website https://www.reverbnation.com/johnmartinclassicalguitarist Join this channel to get access to perks: https://www.youtube.com/channel/UC_c8KysI2G9rAbNyD1dVd6g/join --- Send in a voice message: https://podcasters.spotify.com/pod/show/jeffrey-s-reynolds/message Support this podcast: https://podcasters.spotify.com/pod/show/jeffrey-s-reynolds/support

The Dean's List with Host Dean Bowen – This week at Waterbrook Christian Academy's open house, I share insights on the profound benefits of Classical Christian Education. Notre Dame researchers reveal that students from this educational background excel in community involvement and gratitude, outperforming peers from other school types. Join us to see how our approach shapes responsible, impactful individuals...

Our guest today is Robby Cook, who is the chef at Coral. Coral opened in October 2023 and is located next to Grand Central Station in Manhattan.Robby's path to becoming a successful sushi chef is unique and impressive. He joined us on Episode 37 in 2016, when he was the executive chef at Morimoto, and talked about his intriguing journey to becomimg a successful sushi chef.Inspired by the world of sushi and its tradition, Robby studied at the California Sushi Academy. After graduation, he proved his talent at notable restaurants in New York, including BondST and Morimoto.There used to be a belief that great sushi could be made only by Japanese chefs trained in Japan, but now we see so many cases to disprove this idea. Robby is a perfect example: he not only understands the traditional value of sushi, but communicates it effectively to a global audience with his own sushi-making philosophy.On this episode, we will discuss how a young American decided himself to becoming a sushi chef, how he managed to hone his skills to become one of the top talents in the U.S., his sushi-making philosophy behind his omakase menu at Coral, his advice for future sushi chefs and much, much more!!!-----THE NOTO PENINSULA EARTHQUAKE DISASTER RELIEF As you may know, a major earthquake struck Japan's Noto Peninsula in Ishikawa Prefecture on January 1st. The death toll keeps climbing and the damage to the beautiful region is tremendous. Importantly, 10 of the 11 sake breweries in the Noto Peninsula were completely or partially destroyed. So if you can, please donate through reliable organizations including: The Japanese Red Cross https://www.jrc.or.jp/english/relief/2024NotoPeninsulaEarthquake.html Peace Winds America: A fundraiser by US-Japan Foundation/US-Japan Leadership Program https://www.globalgiving.org/fundraisers/49472/ 　The Ishikawa Sake Brewers Association https://www.ishikawa-sake.jp/index.php　(the donation account details) https://www.ishikawa-sake.jp/images/97-1.pdf) Heritage Radio Network is a listener supported nonprofit podcast network. Support Japan Eats by becoming a member!Japan Eats is Powered by Simplecast.

The Dean's List with Host Dean Bowen – Classically educated students dissect Merrick Garland's speech on the 59th anniversary of the Selma March, highlighting the clash between voter rights and restrictions. They use their knowledge of rhetoric to question claims about voting attacks, emphasizing the need for critical thinking in education and the importance of a classical education in today's political and social landscape.

Tnfroisreading Woke History the last Diamond performing half time, Coretta Scott was a Queen before she was a King, Living to Eat   I am staying awake long enough to watch the 1/2 time show… Confessions made Ur-sher the last Black Diamond artist…a decade ago.   From SNCC to BLM-Youbg people understand the assignment…this -ish just a distraction.      Jonathan Majors ain't nothing but “breath and britches” —-Bernice Scott, her granddaughter's namesake, Mrs. Coretta Scott King's clap

Classical Education for Students with Special Needs: Classical Education has a reputation for targeting the brightest and most precocious students and providing far too rigorous a path for any but the child prodigy. But is that actually the case? Can classical education provide a path forward for students with special needs? Indeed, classical education contributes to intellectual growth regardless of a child's starting point! Read on to discover the transformative power of this educational philosophy, especially when tailored for special needs students. We'll discuss the universal adaptability of classical education, showcasing its ability to nurture intellectual growth, foster independence, and provide a holistic educational experience for children with unique learning requirements. Learning practical strategies for fostering independence in children with ADHD and dysgraphia further underscores the flexibility of classical education, making it a valuable choice for families navigating learning challenges. Grounded in the principles of Truth, Goodness, and Beauty, classical education emerges not only as an inclusive educational approach but as a beacon of hope and empowerment for families navigating the intricate terrain of special needs homeschooling. Show notes + full transcript: https://www.humilityanddoxology.com/classical-education-special-needs Join Made2Homeschool for exclusive content and community https://www.made2homeschool.com/a/2147529243/KNcPGL3t Homeschool Preschool: https://www.humilityanddoxology.com/how-we-homeschool-preschool-2/ Homeschool Planning Guide: https://www.humilityanddoxology.com/homeschool-planning-guide Subscribe, rate, and review ⁠⁠Homeschool Conversations with Humility and Doxology⁠ Follow Amy @HumilityandDoxology on ⁠⁠Facebook⁠⁠, ⁠⁠Instagram⁠⁠, and ⁠⁠YouTube⁠ Follow Humility and Doxology Online: Blog ⁠⁠https://www.humilityanddoxology.com/⁠⁠ Facebook ⁠⁠https://www.facebook.com/HumilityAndDoxology⁠⁠ Instagram ⁠⁠http://instagram.com/humilityanddoxology⁠⁠ YouTube: ⁠⁠YouTube.com/humilityanddoxology⁠⁠ Book Lists ⁠⁠https://www.amazon.com/shop/humilityanddoxology⁠⁠ This podcast and description contains affiliate links. --- Send in a voice message: https://podcasters.spotify.com/pod/show/humilityanddoxology/message